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Allergies are a common chronic disease and considerably decrease the quality of 
life for affected individuals. Understanding the immune responses during allergic 
diseases is essential for both diagnosis and the development of effective 
therapies. The route of sensitisation to allergens is one factor that influences the 
immune response and the outcome of allergic diseases and both human and 
animal studies have highlighted IL-4Rα as an important component in the 
induction of allergy. The aim of this study was to investigate the contributions of 
the route of sensitisation to allergens with focus on the significance of cell 
specific expression of IL-4Rα in the onset of allergy. 
 
The route of sensitization to Anisakis pegreffii influences the outcome of 
experimental allergic asthma 
Worldwide, increasing numbers of allergies to the fish parasite Anisakis pegreffii 
are reported. Anisakis can cause allergies after accidental infection of humans 
and in the occupational environment. Currently it is not clear if different exposure 
routes to Anisakis affect the development of allergic asthma and if they have an 
influence on the immune response. To address these questions, the present 
study investigated immune responses and disease development after Anisakis 
live infection and after nasal sensitisation in a mouse model of allergic airway 
disease. We showed that the route of sensitisation influences the outcome of 
Anisakis pegreffii induced allergic asthma and demonstrated important 
contributions of IL-4Rα to the underlying immune response. 
 
Alternatively activated macrophages are not necessary for the 
development of experimental allergic lung inflammation 
Development of alternatively activated macrophages (AAM) is induced by signals 
of IL-4Rα. Alternatively activated macrophages (AAM) are a feature of allergic 
asthma in clinical and experimental investigations but their role in the 











asthma was used to compare mice deficient in AAM (LysMcreIL-4Rα-/lox mice) with 
control mice. We found that the presence of AAM at early stages of allergic 
airway inflammation these cells was not required for the onset of the disease. 
 
Smooth muscle IL-4Rα is not required for experimental allergic asthma 
In vitro studies have suggested that IL-4Rα signalling on airway smooth muscle 
cells (ASMC) is critical for airway inflammation and airway hyperresponsiveness. 
Using mice deficient for IL-4Rα in ASMC, the in vivo effects of impaired IL-4Rα 
signalling in ASMC on the outcome of asthmatic disease were investigated. The 
impairment of IL-4Rα on SMC had no effect on major aetiological markers of 
allergic asthma. These findings suggest that IL-4Rα responsiveness in airway 




The present study showed the importance of the route of sensitisation and IL-
4Rα in the development of allergy to Anisakis pegreffii. The use of in vivo models 
of experimental allergic asthma revealed that the route of sensitisation can 
influence the underlying immune response of the disease. Furthermore by using 
mice with cell specific deficiencies in IL-4Rα it was demonstrated that expression 
of this receptor on smooth muscle cells and macrophages is not essential for the 
development of acute experimental allergic airway disease, as it has been 




















































1 General Introduction 
1.1 Allergy-General Overview 
 
1.1.1 Prevalence of allergies 
 
Allergy represents one of the most prevalent chronic diseases worldwide with 
affected individuals having considerably reduced quality of life. The number of 
reported allergies has increased worldwide in the last decades, and it is 
estimated that 20% of the world’s population is affected by various forms of 
allergic diseases, though the prevalence varies considerably between different 
countries.1 The reason for these regional differences is not understood likely 
to be affected by an individual’s life style and genetic predisposition. 
 
A worldwide study in 1998 on the prevalence of allergic symptoms in children 
showed a variation from 1.4 to 39.7% between different study centres.2 A 
follow- up study reported a rise in prevalence in most places within 7 years.3 
In South Africa, allergic prevalence is currently estimated 15-20% in children 
and was increasing over the last years3. As allergic diseases are 
predominantly reported in developed countries they might be connected with a 
“westernized” way of living.4 In rural communities allergic diseases appear to 
be less common, while urban environments appear to increases the risk of 
developing allergies.5, 6 In twenty European countries, large variations in 
allergy prevalence have been shown between study centres and it remains 













Figure 1.  World map showing direction of change in prevalence of asthma symptoms 
for children from 13–14 years . Prevalence in South Africa increased over the last years. 
Each symbol represents a study centre. Blue triangle=prevalence reduced. Green 




There is a strong hereditary component in the disposition to allergic diseases. 
Children with allergic parents or a family history of allergies have an increased 
risk of developing allergies. The role of genetic variances in allergic disease 
has been recognised for some time and polymorphisms in over 70 candidate 
genes have been discovered, many of them involved in immune responses.7 
Whereas the link between allergies and genetic factors may contribute to 
regional differences in the prevalence of allergies, it does not explain its 
increasing trends in many parts of the world. Genetic susceptibility also seems 
to be influenced by environmental factors such as exposure to pollutants or 
allergens which have different effects on different genotypes.8  
 
An explanation for the influence of environmental factors is the hygiene 
hypothesis, which was first described in 1989.9 This hypothesis is based on 
epidemiological studies which show that exposure to infections in early 
childhood reduce the risk of developing allergies.10 Immunological 
mechanisms to explain this hypothesis conclusively are still missing.11, 12 It 












infections or microbial components induces the development of a protective 
Th1 type immune response to the allergen. This prevents a Th2 type and 
therefore allergic immune response.11 Another mechanism might be the 
development of suppressive immunoregulatory responses to chronic or 
repeated infections.13 Practical implications from the hygiene hypothesis for 
the prevention and treatment of allergies are limited and an association 
between vaccinations or antibiotic usage, as sometimes suggested in the 
media, has not been shown.14, 15 Some authors also questioned the validity of 
the epidemiological studies.16, 17 However, the hygiene hypothesis can be 
useful as a guideline for future epidemiological or immunological studies into 
causes and prevalence of allergies.18 
 
1.1.2 Definition of Allergy 
 
Allergy is an immunological disorder where the balance of the defence 
mechanisms between protection and overreaction is disturbed.  The term 
allergy was introduced in 1905 by von Pirquet to describe a situation where an 
external agent causes some form of changed or altered response in the 
recipient which could be either immunological protection or hypersensitivity.19 
Over time this definition has changed and today allergy is only used in the 
latter meaning.20 The definitions used here are recommended by the World 
Allergy Organisation (WAO) and the World Health Organisation (WHO) with 
the intention of harmonising the nomenclature of allergic disorders.21, 22  
 
Hypersensitivity reactions are reproducible symptoms in response to 
substances at doses tolerated by normal individuals. The term allergy is 
restricted to hypersensitivity reactions mediated by allergen specific 
immunological mechanisms.22 The immune response in allergies is either 
antibody or cell mediated. In the majority of cases, allergen specific IgE 
antibodies induce the allergic response. Non-IgE mediated allergic reactions 
can be triggered by IgG antibodies as in anaphylaxis, or by allergen specific 
lymphocytes, as in contact urticaria or non-atopic asthma.22-24 The tendency 












specific IgE antibodies is called atopy. Atopic individuals are therefore 
predisposed for the development of allergic symptoms and the diagnosis of 








IgE-mediated Asthma Non-IgE-mediated Asthma
 
Figure 2. Allergic and non-allergic asthma.  Asthma resulting from immunological reactions 
should be called allergic asthma. Most cases are initiated by IgE antibodies, but non-IgE 
mediate asthma has been reported. Adapted from Johansson, 2004.22 
 
 
Hypersensitivity reactions have been classified by Coombs and Gell into type 
I-IV reactions 25 and this classification is still widely used. Typical IgE 
mediated allergies are immediate type I reactions under this classification, 
characterised by the release of proallergic mediators such as histamine, 
leukotrienes and prostaglandins from mast cells and basophils. However, 
besides IgE antibodies, chronic effects and other components of the immune 
system, such as T cells, are involved in the pathogenesis of allergies and the 
usefulness of this classification for describing allergic reactions has been 
questioned.26 
 
This review will focus on IgE-mediated allergies with special emphasis on 















1.1.3 Symptoms of allergic diseases 
 
Allergic diseases affect individuals in different ways and symptoms vary 
considerably depending on the target organ. Manifestations of allergies 
include conjunctivitis, rhinitis, asthma, dermatitis, urticaria and anaphylaxis 
and often occur in different combinations. The reason why patients develop 
only certain signs of allergy is not understood and manifestations may change 
with age or remit completely.  
 
Skin manifestations of allergic diseases are dermatitis and urticaria. Both are 
accompanied by pruritus and a typical sign of dermatitis is eczema, with hives 
and wheals being a sign of urticaria.   
 
Symptoms of allergic rhinitis are sneezing, itching, increased nasal discharge 
and often itching of the palate and inner ear. Conjunctivitis with running and 
itching eyes is found together with rhinitis in many cases. Both manifestations 
are often seasonal, e.g. in pollen allergies but can also be perennial, 
especially if indoor allergens are involved.27 
 
A more severe manifestation of allergy of the respiratory tract is allergic 
asthma, which often occurs together with allergic rhinitis.28 Allergic asthma is 
responsible for 80% of childhood and over 50% of adult asthma.1 Shortness of 
breath, wheezing and cough in consequence of bronchoconstriction and 
excessive mucus production are normally transient, but patients can develop 
chronic inflammation of the airways after long term allergen exposure.  
 
Anaphylaxis is a severe systemic response occurring usually within minutes 
after exposure to allergens and is fatal in approximately 1% of cases.29 Skin, 
cardiovascular, respiratory and gastrointestinal systems can be affected and 
patients may go into anaphylactic shock due to a sudden collapse of the 















The general definition of an allergen is an antigen that causes allergic 
diseases,22 normally an IgE-mediated allergic disease. According to a 
standardised nomenclature that has been proposed by the WHO, allergens 
are designated according to the species name of their source as follows: first 
three letters of the genus name, first letter of the species and a number (e.g. 
Fel d1 for house cat Felis domesticus).30 
 
Allergens are in most cases proteins that are able to induce an IgE memory 
response, but specific features that distinguishes them from non-allergenic 
proteins are not defined.31 The particle size may be important for the kind of 
allergic response that is induced by a specific allergen. Large particles, such 
as grass pollen, may not be able to enter the lungs and cause allergic asthma, 
but are rather deposited in the nose or throat where they may induce allergic 
rhinitis.32  
 
No structural characteristics of allergens are defined and every protein that is 
able to reach and stimulate immune cells may be able to induce an allergic 
response.33 Protease activity has been described for some allergens, such as 
the house dust mite allergen Der p1.34 Enzymatic activity was associated with 
increased inflammatory responses,35-37 but enzymatic activity is not a common 
feature of allergens, and enzymes in general are not more allergenic.32 
Characteristics of some food allergens are their resistance to enzymatic 
digestion and processing, high abundance in the food, and several linear IgE 
binding Epitopes.38  
 
The observation that allergens show cross-reactivity with other allergens, 
sometimes from very different sources, has initiated bioinformatical 
approaches to identify common structural features of IgE binding of 
allergens.39 More information about three-dimensional structures 40 and 
binding Epitopes 41-43 of allergens is becoming available and may enable 













1.1.5 Routes of exposure to allergens 
 
Most allergens in IgE mediated diseases enter the body by inhalation or 
ingestion, but some may also be injected, such as insect venoms or drugs. 
Aeroallergens can occur seasonally, such as grass and tree pollen, or 
perennially, such as dust mite, moulds or domestic animal allergens. The 
appearance of allergic symptoms at certain times of the year is often the first 
indication of the nature of the allergen. Allergic rhinitis and asthma, but also 
atopic eczema, are the most common symptoms in response to 
aeroallergens.27 
 
Development of allergic reactions is also observed after exposure to 
aerosolised allergens in the work place. Symptoms of IgE-mediated 
occupational allergies are allergic rhinitis, asthma or urticaria, whereas contact 
dermatitis is mostly non-IgE, but T-cell mediated.22,45,46,47 In the occupational 
environment it is important to distinguish between immunological mediated 
reactions and reactions that are irritant-induced, as this has implications on 
the treatment and prevention strategies. To distinguish between 
immunological occupational asthma and irritant-induced occupational asthma, 
several criteria have to be considered. Airway hyperresponsiveness, onset of 
asthma after workplace exposure, association of asthmatic symptoms with the 
work exposure and induction of symptoms by the suspected allergen at the 
workplace are required for the diagnosis of occupational allergic asthma.48 
 
Food allergies occur after ingestion of allergens and can be distinguished from 
food intolerance by their immunological mechanism, which mostly involves 
IgE mediated responses. Symptoms of food allergy can involve the skin, the 
respiratory tract and the gastrointestinal tract. Skin manifestations, such as 
eczema and urticaria, often include the lips mouth and throat. Nausea, 
vomiting and diarrhoea are common in food allergies, whereas rhinitis and 












in food allergies and the allergen sources in fatal cases were mostly peanuts 
and tree nuts, but also milk, egg and seafood.49  
 
Small amounts of food allergens can be sufficient to induce a severe allergic 
reaction and patients might not be aware of the food containing allergens. 
Hidden food allergens are often unintentionally introduced during processing 
and preparation of food, and their content may be below the legal requirement 
for labelling. Milk, eggs, fish, crustaceans, shellfish, peanuts, tree nuts, wheat, 
and soy are common hidden food allergens and legislation requires 
declaration in Europe and North America, even if only small amounts are 
found in the food.50 
Food allergens may also become aerosolised during processing and cooking, 
and can induce allergic reactions after inhalation. This is of particular 
importance in the occupational environment where 10% of asthma is induced 
by aerosolised food.51 In seafood processing industries, workers are exposed 
to allergens during cleaning, cooking or fish meal production and the 
prevalence of allergic symptoms ranges from 3-36%.48 
 
Parasites hidden in food are another source of allergens that has long been 
underestimated. Anisakis spp. is a group of nematode parasites frequently 
found in fish, molluscs and shellfish that are designated for human 
consumption.52 The species most commonly found in seafood, A. simplex and 
A. pegreffii, have a worldwide distribution and are closely related to the human 
parasite Ascaris lumbricoides.52, 53 After accidental infection with the live L3 
larvae, humans develop a gastrointestinal zoonosis named anisakiasis, 
characterised by abdominal pain, nausea or vomiting, that is often 
misdiagnosed as gastric ulcer.54 During Anisakis infection, IgE mediated 
hypersensitivity reactions may occur 55, 56 and Anisakis related allergies have 
also been reported after consumption of fish contaminated with dead 
parasites.57 In regions with high fish consumption, Anisakis is an important 
inducer of allergic reactions and was the most frequent cause of food-related 
anaphylactic reactions in a recent study in Spain.58 Hidden Anisakis allergens 
are also an important factor in occupational environments. A recent study in 












sensitisation to Anisakis allergens, that was associated with allergic symptoms 
59 and several cases of occupational Anisakis allergies have been reported 
from Spain.60, 61 
 
 
Figure 3: Visceral organs of Thyrsites atun (snoek) infected with Anisakis pegreffii L3 
larvae.  Most parasites live in the visceral cavity (arrows) but few individuals may migrate into 
the muscle of the host. Humans might get exposed to Anisakis allergens after consumption or 
processing of contaminated fish.   
 
 
1.1.6 Diagnosis of allergy 
 
For the diagnosis of an allergic disease it is essential to prove an 
immunological mechanism behind the symptoms and to identify the allergen 
to which the patient is reacting.22 For the medical history of an allergic 
disorder, it is important to find out about the symptoms and the situation when 
the symptoms occur, in order to identify the allergens to be considered for 
more specific tests.  
 
Most allergies are mediated by allergen-specific IgE, and their detection is 
important for diagnosis. Usually, the first recommended test is a skin prick test 
(SPT) where a small amount of allergen is applied onto the skin. This induces 
the release of inflammatory mediators by mast cells and provokes a skin 
reaction if the patient is sensitised to the allergen. Allergens can also be 
applied by subcutaneous injection or scratch test.27 Diagnosis of food allergies 
is complicated by the fact that SPT results are often unreliable and may give 












controlled food challenge (DBPBFC) under close supervision is 
recommended.62, 63  
 
In vivo diagnostic tests are fast, cheap and mostly reliable tests, but have 
some disadvantages that need to be considered. These methods bring the 
risk of anaphylactic reactions after allergen application onto the skin and are 
not reliable if the patient is having anti-allergic medication. Standardised 
allergen preparations are often not available for new or uncommon allergens, 





Figu re 4. Positive skin-prick test. A1/2: allergen preparations;  
S: saline (negative control; H: histamine (positive control)  
 
 
Several in vitro methods are available for allergy diagnostic in blood samples. 
Commercially available systems allow measurement of allergen specific IgE 
concentrations in small blood samples by Radioallergosorbent test (RAST) or 
Enzyme linked immunosorbent assay (ELISA). Basophil activation assays 
measure mediator release such as histamine or leukotrienes after in vitro 
stimulation with allergens.27 These methods are particularly useful for testing 
self-made allergen preparations or non-purified samples containing allergens 















Diagnosis of allergic asthma requires the proof of airway hyperresponsiveness 
(AHR) in addition to the general allergy tests. Changes in airway resistance in 
response to unspecific bronchodilators such as methacholine are indicators of 
AHR and can be measured by spirometry or whole body plethysmography 
(WBP).27 
 
Diagnosis of Anisakis allergies mostly relies on specific IgE determination by 
ELISA or Western Blot. Hypersensitivity reactions due to live infection with 
Anisakis larvae are a combination of parasite infection with allergic reaction, 
and diagnosis in this special case can be performed by endoscopic 
examination and identification of the worm. 
 
1.1.7 Therapy of allergic diseases 
 
The first step in developing allergic diseases requires the sensitisation to an 
allergen, usually characterised by establishment of an IgE memory response. 
As discussed earlier, the reason why certain people get allergies is poorly 
understood and seems to be dependent on genetic and environmental 
conditions as well as the personal history of the patient. Therefore no 
strategies are known so far that can prevent allergic sensitisation but 
minimising risks is recommended by avoiding exposure to potential allergens 
at home or at the workplace, especially when a family history of allergy exists. 
When sensitisation to an allergen has been diagnosed, avoiding exposure is 
the first step preventing establishment of allergic symptoms. 
 
Allergen immunotherapy is an effective treatment for IgE-mediated allergic 
rhinitis and asthma 65 and is the only currently available strategy for curing 
allergic diseases rather than treating symptoms. This is achieved by repeated 
administration of allergen preparations over a long period, often several years. 
Subcutaneous injection has been the preferred way of administration but 
sublingual protocols have been developed to reduce the risk of severe side-
effects and to improve efficiency.65 The principle of immunotherapy relies on 












After immunotherapy, patients have increased levels of allergen-specific IgG 
antibodies that may prevent binding of IgE to allergens. Numbers of effector 
cells such as mast cells and basophiles were reduced and an increase in 
allergen specific regulatory T cells as well as a switch from a Th2 type to a 
Th1 type immune response was observed.66 Immunotherapy is not efficient in 
all patients, especially when they have developed allergies against multiple 
allergens or show perennial symptoms.67   
 
Several pharmacological strategies exist for allergy treatment and its 
efficiency is often dependent on the type of symptoms and personal response 
to the drugs.  
Antihistamines are the first medication of choice because of their efficacy, 
rapid onset, long duration of activity and low side effects. They are selective 
antagonists of the H1 histamine receptor thereby inhibiting the inflammatory 
effects of histamines, an important mediator in allergic diseases. Second 
generation antihistamines, which lack the sedative effects of first generation 
drugs, are an effective treatment, especially for allergic rhinitis 68 and urticaria. 
Antihistamines reduce asthma symptoms 69, 70 but are not considered an 
effective asthma treatment.71  
 
Leukotriene inhibitors are a relatively new class of allergy drugs and are 
leukotriene receptor antagonists. They have been shown to be efficient in 
asthma and allergic rhinitis therapy with low risk side effects.71-73 
 
Humanised anti-IgE monoclonal antibody was effective especially in patients 
with severe, poorly controlled asthma, and might be a new treatment option 
for this patient group.74 Treatment with anti-IgE antibody reduced 
inflammatory cell numbers in the lung and nose and circulating IgE in the 
blood of patients with allergic rhinitis and asthma, which correlated with an 
improvement of symptoms.75 
Treatment of allergic asthma requires special medication targeting the airway 
symptoms. β2 adrenergic receptor agonists are widely used for the immediate 
treatment of acute asthmatic symptoms, and their activity as bronchodilators 












in reducing side effects by improving specificity for the β2 receptor and 
increasing the duration of activity.71  
 
For the long term control of asthma, inhaled corticosteroids (ICS) are the most 
effective treatment currently available. Prolonged treatment on a scheduled 
basis leads to sustainable improvement of lung function and asthmatic 
symptoms 76 by controlling the underlying inflammation in the airways.77, 78 
The introduction of ICS has significantly reduced the side effects of systemic 
corticoid treatment which has limited their usefulness in allergy treatment for a 
long time.71  
 
Currently available treatments are effective in controlling a wide range of 
allergic symptoms but they are not able to cure allergic diseases, and 
symptoms recur when intake is stopped. Therefore a better understanding of 
the mechanisms behind allergies is essential for the development of effective 
treatments. The development of new technologies for fast and cheap 
detection of single nucleotide polymorphisms (SNP) in individual genomes will 
make the detection of disease associated genes in individual patients possible 
79 and allow the development of personalised therapeutic strategies for 
allergies and asthma.80 
 
1.1.8 Immunomodulatory strategies in allergy therapy 
 
A better understanding of immune responses in the development of allergies 
has led to several immunomodulatory approaches for new therapeutic 
strategies.81 In most cases, antagonists for cytokines which were believed to 
play important role in allergy development were tested in clinical trials.  
 
Interleukin (IL-)-5 is an important effector molecule for the differentiation and 
recruitment of eosinophils.82 As eosinophils are associated with allergic 
diseases it was believed that these cells are important in disease 
development. Administration of monoclonal anti-IL-5 antibodies reduced 












asthma and dermatitis. However, the efficiency of this antibody is still being 
investigated in long term studies. Strategies that targeted IL-4 also did not 
bring considerable improvement in allergic symptoms and this approach is no 
longer followed. Results of anti-IL-4 and anti-IL-5 trials also led to the 
conclusion that these molecules as well as eosinophils might not be crucial in 
allergy development.83 
 
There is evidence from animal models 84-86 and human studies 87 that IL-13 
has an important role in the pathogenesis of allergies and asthma. AHR, 
mucus production and eosinophilic inflammation are dependent on IL-13 or IL-
4Rα, the common part of IL-4 and IL-13 receptors.88 Several monoclonal anti-
IL-13 antibodies and IL-4Rα antagonists are currently being tested in clinical 
trials.89  
Blocking of TNF-α, which is also associated with asthmatic diseases, has 
resulted in considerable improvement of symptoms in clinical trials and might 
be a promising target for at least a subset of patients with severe asthmatic 
diseases.90  
 
Other immunomodulatory strategies include administration of toll like receptor 
(TLR) agonists like LPS or CpG-DNA in order to shift the cytokine response 
from an allergy associated Th2 response to a protective Th1 response.89  
 
Most of the immunomodulatory therapy strategies are still in trial phases and 
their efficiency and safety for the treatment of allergic diseases remains to be 
proven. As allergies are complex diseases with a large variety of 
manifestations, many therapies may only be efficient in a subset of patients. 
The immune system also shows a degree of redundancy, and targeting a 
specific molecule might not help, due to compensation by other parts of the 
immune response. Therefore, further research on the immune responses 














1.2 Allergy-Immunology of allergic responses 
 
1.2.1 Route of sensitisation influences the immune response in 
allergy 
 
In allergy, the immune system generates a response to harmless, non-
infectious antigens that are tolerated by healthy individuals. It is important to 
understand the immunological mechanisms that are responsible for this 
disregulated immune response in order to provide effective therapies and 
diagnostic tools for allergic patients. 
 
The route of sensitisation to allergens is one factor that influences the immune 
response and the outcome of allergic diseases. The magnitude of IgE 
responses to allergens has been shown to be dependent on differences in the 
route of  sensitisation.91-93 In one study, aerosol exposure and dermal 
sensitisation induced a stronger IgE response than intraperitoneal (i.p.) 
sensitisation and severity of disease symptoms correlated with antibody 
titres.94 Development of AHR in the absence of IgE was found only after i.p. 
allergen sensitisation, but not after nasal sensitisation in animal models of 
allergic airway disease.95, 96 The route of sensitisation to birch pollen 
influenced antibody and cytokine responses in a mouse model, with 
production of the cytokines IL-5 and IL-13, but not IL-4, dependent on the 
route of sensitisation to the allergen.92  
 
In Anisakis allergy, the influence of the route of sensitisation is of particular 
interest as sensitisation can occur after infection with the live parasite. 
Anisakis is an unusual case where a parasitic infection may induce allergic 
sensitisation, whereas other nematode infections have been associated with 
protection from allergic reactions.13, 97 It is still controversial whether contact 
with Anisakis proteins is sufficient for allergic sensitisation, or if live infection is 
required.56, 98 Clinical studies with Anisakis allergic patients gave conflicting 
results.99, 100 A recent study in our laboratory demonstrated an increased risk 












exposure to aerosolised proteins in the occupational environment. This study 
also demonstrated that mice show allergic airway symptoms after live 
infection and oral protein challenge.59 In the animal study, the immune 
response and severity of allergic symptoms was dependent on the route of 
sensitisation, with more severe symptoms after live infection.  
 
It is apparent from these studies, that the route of sensitisation has an 
important influence on allergen specific antibody and cytokine responses and 
on the outcome of allergic diseases. The immunological mechanisms behind 
these observations are not entirely clear and further investigations of the 
immune responses after different means of sensitisation to Anisakis, and of 
the general immune mechanisms in allergy and asthma are required.   
  
1.2.2 Innate and adaptive Immunity 
 
Immune responses are mediated by leukocytes that provide innate and 
adaptive mechanisms of protection. The innate immune response is the first 
line of defence against invading pathogens and has cellular and humoral 
components. The latter consist of plasma proteins of the complement system 
that can bind to invading microorganisms. Complement proteins can kill 
pathogens directly by cell lysis or they mark them for phagocytosis by immune 
cells, a process called opsonisation.101  
 
Phagocytotic cells, such as macrophages and neutrophils, recognise 
opsonised particles by complement receptors, but also by pattern recognition 
receptors (PRR), that are specific for characteristic pathogen-associated 
molecular patterns (PAMPs). Several PRR are expressed by immune cells, 
e.g. toll-like receptors, mannose receptor or C-type lectins, and allow a 
specific recognition of invading pathogens.101 In contrast to the receptors of 
the adaptive immune system, they do not change their antigen specificity. 
Natural killer (NK) cells are specialised cells of the innate immune system for 
identification and killing of virus infected cells or tumour cells. Pathogens that 












eosinophils by their release of cytotoxic proteins, such as eosinophil 
peroxidase (EPO), major basic protein (MBP) or eosinophil cationic protein 
(ECP).102 Mast cells and basophils, upon activation, release inflammatory 
mediators such as histamine, prostaglandins or leukotrienes and are directing 
other leukocytes to the site of inflammation by cytokine release.103 Mast cells 
are long living cells that can be found in all tissues whereas basophils are 
circulating blood leukocytes.103 The innate immune system provides several 
effective mechanisms for controlling invading pathogens. In case the innate 
immune mechanisms are not sufficient for clearing the infection, the adaptive 
immune defence gets activated. 
 
The adaptive immune response provides an effective and specific protection 
against invading pathogens and creates and immunological memory, that can 
get activated in short time after reinfection. Characteristic for adaptive 
immunity is the generation of antigen receptors in a random process in T and 
B lymphocytes, which are virtually able to recognise all invading pathogens. 
Antigen presenting cells (APC), including dendritic cells and macrophages, 
are essential in this process. They present antigen-peptides on MHC-II 
molecules on their surface to CD4+ T-helper (Th) cells. Recognition of the 
peptide-MHC-II complex by the T cell receptor induces clonal expansion and 
activation of the Th cell. APC provide further signals to Th cells by the release 
of cytokines and expression of co-stimulatory molecules on their surface, and 
influence the development of Th1 or Th2 type immune responses. These 
cytokine signals are dependent on preceding innate responses and APC are 
an important link between innate and adaptive responses. After activation, Th 
cells start cytokine expression and induce the generation of a specific 
antibody response by activating B cells that recognise the same antigen. 
Depending on co-stimulatory cytokine signals, B cells produce several 
different types of antibodies, i.e. IgM, IgG, IgE, IgA or IgD. After activation by 
T cells, B cells can differentiate into antibody producing plasma cells or 
memory B cells. Together with memory T cells, they provide an immunological 
memory that is able to launch a rapid response after at the next encounter 













Adaptive immune responses need to be tightly controlled in order to prevent 
development of immune responses against non-pathogenic antigens. The 
random process of antigen receptor generation may produce receptors 
against self-antigens that need to be eliminated in order to prevent 
autoimmune diseases. Furthermore, control mechanisms are necessary to 





Adaptive and innate immune responses require interactions of different types 
of immune cells as well and resident cells. Essential in the regulation of 
immune responses are cytokines, small messenger proteins that are 
produced by various cells in response to a number of stimuli and can be 
recognised by any cell expressing the appropriate cytokine receptor. Cytokine 
production is transient and they regulate differentiation, proliferation, activation 
or recruiting of cells. Their mode of action can be autocrine, by binding on 
receptors on the same cell that secreted it, or paracrine, by binding on other 
cells in close proximity.88 Cytokines include several groups of signalling 
molecules, including interleukins (IL), chemokines and interferons (IFN). 
Theses names, given at the time of their discovery were used to describe their 
functions or target cells (e.g. interleukin: cytokine acting between two 
leukocytes) but increasing knowledge about their functions revealed a more 
complicated situation and one cytokine may be produced in and recognised 
by a variety of different cell types where they induce different reactions.88 
 
1.2.4 Differentiation of T-helper (Th) subsets 
 
Allergic responses are associated with Th2 type immune responses which are 
also induced by infections with parasitic helminths. The term originated from 












as Th1 and Th2 cells according to differences in the cytokine profile 
expressed after stimulation. Th1 and Th2 polarised cells have later been 
identified in humans and seem to have similar properties and implications on 
the immune response 105. Since the present study investigated mouse models 
of allergic airway responses, this review is focused on the murine immune 
response. 
 
The cytokines produced by the different T helper cells are, among others, IFN-
γ for Th1 cells and IL-4, IL-5 and IL-13 for Th2 cells.106 These cytokines were 
subsequently named as Th1 and Th2 cytokines respectively. A third T-helper 
subset are Th17 cells, secreting IL-17A and IL-17F.107  
 
Th1 type immune responses normally develop after microbial infections and 
intracellular pathogens whereas Th2 type responses are induced by 
extracellular parasites, such as nematodes or trematodes, but also in allergic 
reactions.88 Th1 and Th2 type responses can be distinguished by their 
antibody profiles. Th1 cells, by secretion of IFN-γ, induce production of IgG2a 
and IgG2b antibodies in B cells, whereas Th2 cells induce the production of 
IgE and IgG1.108 IL-13 signals are important for the class switch to IgE, as IL-
13 receptor deficient mice show an impaired IgE response, whereas IL-4 may 
be responsible for the production of IgG1.109 Th17 functions are not as well 
defined, but are essential for clearance of several microbial infections,110-112 
and are also associated with asthmatic symptoms 113-116 and autoimmune 
diseases.117-119  
 
Differentiation of naïve T cells into distinct T-helper cells subset is dependent 
on the signal strength, nature of the antigen presented by APC120,121 and the 
cytokine environment. For development into Th1 cells, IL-12 and subsequent 
IFN-γ signalling is essential, and IL-18 provides further signals for terminal 
differentiation.122 IL-4 is crucial for Th2 development and induction of a Th2 
type immune response.123, 124 Differentiation of naïve T cells into Th17 cells 
requires IL-6 together with TGF-β, and IL-23 promotes Th17 effector 












helper cell types. In the presence of IL-4 and IFN-γ the development of Th17 
cells is inhibited, whereas IL-4 alone inhibits Th1 differentiation and IFN-γ 
alone inhibits Th2 differentiation.127-130  
 
T regulatory (Treg) cells are a fourth subset of CD4
+ T cells, which are 
characterised by expression of CD4, CD25 and the transcription factor 
Foxp3.131 These naturally occurring CD4+CD25+Foxp3+ Treg cells are essential 
for controlling self tolerance and inflammatory immune responses and are a 
distinct T cell lineage.132 The mechanisms of immunosuppression by Treg cells 
are not completely understood, but direct cell contact, IL-10 and TGF-β 
production seem to be involved.133  
 
1.2.5 Immune response in allergy and asthma 
 
Allergy is an inflammatory disease caused by a Th2 type immune response. 
As discussed earlier, the reasons for the induction of this response to 
otherwise harmless allergens in susceptible individuals are poorly understood 
and genetic factors seem to play an important role. This is supported by the 
observation that different inbred laboratory mouse strains also show the 
tendency of developing either a Th1 response (e.g.C57/Bl6 mice) or a Th2 
response (e.g. Balb/c mice). 
During the sensitisation phase, an immune response to the allergen is 
established at the first encounter with the allergen. Dendritic cells present the 
allergen to undifferentiated T-helper cells. At this stage, the presence of IL-4 is 
critical to drive the differentiation into allergen specific Th2 cells.124 The initial 
source of this cytokine is not defined, but several cells of the innate immune 
system have been shown to produce IL-4, such as mast cells and basophils. 
Allergen specific Th2 cells stimulate B cells to produce allergen specific IgE or 
IgG1 antibodies. The establishment of an allergen specific T cell and B cell 
response to the allergen is critical for the further development of the disease 
as these cells establish a memory response that can get activated after a 












Allergen specific IgE binds to FcεRI, the high affinity receptor for IgE on mast 
cells and basophils.103 Mast cells are now not only sensitised for activation 
upon renewed contact with the allergen, but IgE binding without antigen 
contact already induces cytokine production and upregulation of FcεRI on 
mast cells, thereby decreasing the threshold for activation.134 This effect might 
be counterbalanced by allergen specific IgG1, that binds to the inhibiting 
FcγRIIB-IgG receptor.135 Crosslinking of FcγRIIB and FcεRI by allergens 
inhibits degranulation of mast cells, and a balance of activating and inhibiting 
signals by Fc-receptors might determine threshold levels for activation.136, 137   
 
Crosslinking of IgE/ FcεRI complexes on basophils and mast cells after 
allergen contact induces the release of histamine, leukotrienes, and 
prostaglandins. These inflammatory mediators are increasing vascular 
permeability and smooth muscle cell contraction 134 and are responsible for 
most of the immediate symptoms of allergic reactions, such as 
rhinoconjunctivitis, urticaria, asthma and anaphylaxis, which can occur within 
minutes after allergen exposure.101 
 
Furthermore, expression of cytokines by mast cells and basophils, such as IL-
4, IL-5 and IL-13 recruits Th2 cells and eosinophils and is essential for the late 
phase of allergic reactions and subsequently chronic inflammation. The 
establishment of the late and chronic phase is also supported by histamine as 
it is a chemoattractant for mast cells and eosinophils and increased vascular 
permeability enables the influx of inflammatory cells at the site of the allergic 
reaction.138  
 
Allergic asthma is a chronic inflammatory airway disease and a typical Th2 
type immune response is observed in mouse models. Many studies used a 
model of ovalbumin (OVA) induced allergic airway inflammation to study 
underlying immunological mechanisms.139 To induce a Th2 type immune 
response in mice, the allergens have to be administrated together with an 
adjuvant, such as aluminium hydroxide (alum) or cholera toxin. The mice are 












adjuvant, to induce a Th2 type memory response to the allergen. To induce 
allergic reactions, mice are challenged by nasal administration of the allergen 
without adjuvant. The main pathological characteristics of the allergic airway 
disease in these models are development of hyperresponsiveness of airway 
smooth muscle cells to unspecific stimulation, hyperplasia of mucus producing 
goblet cells in the airway epithelium, airway eosinophilia and peribronchial and 
perivascular inflammation in the lungs.139 
 
The immediate reactions of allergies are dependent on IgE mediated release 
of inflammatory mediators. However, the late and chronic phases are less well 
understood. Complex interactions of immune cells, cytokines and resident 
cells cause the development of disease symptoms and Th2 cytokines play a 
central role in these processes. 
 
For the development of Th2 cells, IL-4 is critical. IL-4 deficient mice fail to 
develop a Th2 type cytokine response 123 and airway hyperresponsiveness, 
eosinophilia and allergen-specific IgE production is impaired when IL-4 is 
neutralised during the sensitisation phase.124, 140 In the effector phase, IL-4 
seems not to be critical anymore for the development of disease symptoms as 
IL-4 neutralisation during airway allergen challenge did not abolish asthmatic 
symptoms.124, 140 
 
IL-13 shares some structural characteristics with IL-4 and has overlapping 
functions. Both are predominantly produced by Th2 cells, mast cells, 
basophils and eosinophils 88 and IL-13 promotes development of alternatively 
activated macrophages, a cell type that has been associated with Th2 type 
immune responses and allergies.141 IL-13 might also have an indirect effect of 
development of Th2 cells and IgE response in mice.88 Murine T and B cells do 
not express IL-13 receptors, but IL-13 deficient mice showed impaired Th2 
cell development and IgE levels.142, 143  
Despite some similarities, IL-13 has distinct functions during the development 
of allergic asthma. The development of AHR, airway eosinophilia and goblet 
cell hyperplasia, main features of allergic asthma, were induced by IL-13 












endogenous IL-13 reduced these symptoms, whereas administration of 
recombinant IL-13 alone was sufficient for induction. Overexpression of IL-13 
in lung epithelium induced mucus production, AHR and airway eosinophilia 
without allergen challenge.144  
 
From in vitro studies, it has been suggested that IL-13 induces AHR by a 
direct effect on contraction of airway smooth muscle cells.145 Goblet cell 
hyperplasia and mucus production are dependent on IL-13 84, 86 and its 
receptor IL-13Rα1.109 Mucus production might be controlled by upregulation 
of GABAA receptors in airway epithelial cells in response to IL-13, as both 
have been shown to be essential for mucus overproduction.146 In conclusion, 
IL-13 seems to be critically involved in the development of typical symptoms 
of allergic asthma, whereas IL-4 is necessary for the initial development of an 
allergen specific Th2 type immune response. However, mice showed goblet 
cell hyperplasia and AHR after inhalation of recombinant IL-4 in the absence 
of IL-13 suggesting a common signalling pathway for IL-4 and IL-13 and a 
degree of redundancy between the two cytokines.147   
 
Other cytokines beside IL-4 and IL-13 are important contributors to the 
development of allergic diseases. IL-5 is a differentiation, migration and 
activation factor for eosinophils 82 and eosinophilia is a characteristic of Th2 
type immune responses. IL-5 deficient mice have impaired numbers of 
eosinophils in the periphery and the lung after allergen challenge. 148,149 
Overexpression of IL-5 in the lung epithelium induced airway eosinophilia 
even in the absence of allergen challenge.150 However, in IL-5 deficient mice, 
eosinophil numbers are highly reduced in the bronchoalveolar space but are 
still present in the perivascular and peribronchial inflammatory cell infiltrate.151 
These data suggest a critical role for IL-5 in the development of eosinophilic 
airway inflammation, but further signals seem to be necessary of the 
regulation of eosinophilic inflammation in allergic asthma. Eotaxin is a 
chemokine of the C-C family with specific chemotactic properties for 
eosinophils, which is critically involved in the development of allergic tissue 
eosinophilia.152 In mice deficient IL-5 and eotaxin, peribronchial and 












between IL-5 and eotaxin regulate eosinophil recruitment in the allergic 
lung.151 
 
Despite the fact that eosinophils have been associated with allergic asthma 
for a long time, the role of these cells in the development of the disease is 
controversial. Eosinophils are able to secrete inflammatory mediators, such as 
leukotrienes, EPO, MBP or ECP but have also been identified as producers of 
the Th2 cytokines IL-4 and IL-13.102 These properties make a prominent role 
of these cells in the development of allergic asthma plausible and numbers of 
eosinophils have been correlated with disease severity in humans. However, 
clinical trials in humans with anti-IL-5 monoclonal antibodies did reduce 
eosinophil numbers in asthmatic patients and did not improve disease 
conditions considerably.83 Experimental models in eosinophil or IL-5 deficient 
mice gave conflicting results. Neutralisation of IL-5 by monoclonal antibodies 
reduced eosinophil numbers dramatically, but had no effect on airway 
hyperresponsiveness,140 whereas IL-5 deficient mice where protected from 
the development of allergic airway symptoms.149, 151 Two different transgenic 
mouse strains with a deficiency in eosinophil generation showed conflicting 
results. ∆dblGATA mice developed AHR and goblet cell hyperplasia 153 
whereas PHIL mice were completely protected from AHR, and partially 
protected from goblet cell hyperplasia.154 An explanation for the differences in 
these transgenic mouse strains might be their different genetic background, 
as ∆dblGATA mice were bred from Balb/c, and PHIL mice from C57/Bl6 
mice.155 Balb/c mice develop stronger Th2 type immune responses and AHR 
in models of allergic airway disease than the C57/Bl6 strain, and contributions 
eosinophils to Th2 type immunity might be less dominant in Balb/c mice. 
 
Further cytokines are involved in development of allergic asthma, probably by 
enhancing Th2 type immune responses. Pulmonary overexpression of IL-9 156 
and IL-25 (IL-17E) 157 increased numbers of Th2 cells and resulted in 
enhanced mucus production, eosinophilia and AHR. 
 
A dual role for IL-17 has been demonstrated in allergic asthma and a role in 












IL-17-receptor are required for allergic sensitisation, expression of IL-17 in the 
effector phase of allergic asthma reduces allergic symptoms by inhibiting 
dendritic cell functions and expression of IL-4 and IL-5.158  
 
1.2.6 IL-4 and IL-13 receptors 
 
IL-4 and IL-13 are playing a central role in allergic sensitisation and 
development of allergies symptoms and show overlapping functions. This is at 
least partially due to signalling through receptor complexes which with the IL-
4Rα chain as a common component.88  
 
The IL-4Rα forms a least two functional receptor complexes. Type I IL-4 
receptor consists of the IL-4Rα and the common γ-chain (γc) of cytokine 
receptors, which is shared with other cytokine receptors, such as IL-2, IL-7, IL-
9, IL-15 and IL-21. The type II receptor consists of the IL-4Rα and the IL-
13Rα1 chain, a low affinity receptor specific for IL-13. IL-4 can signal through 
type I and type II receptors whereas IL-13 only binds to type 2 receptors.88 
For both receptor complexes, intracellular signal transduction is mediated by 
signal transducer and activator of transcription 6 (STAT 6) or insulin like 
receptor substrate (IRS) family proteins.88 IL-4 and IL-13 have different 
affinities to the shared type II receptor complex, which results in different 
intracellular signal quality for IL-4 and IL-13.159 In contrast to the type I 
receptor, the type II IL-4 receptor is not expressed on T cells, explaining the 
dependency of Th2 cell differentiation on IL-4 but not IL-13 signals. The 
difference between the responsiveness of human and mouse B cells to IL-13 
for IgE class switch is also due to different expression of the type II receptor. 
 
With the exception of lymphocytes, type I and type II IL-4 receptors are widely 
expressed throughout different tissue and cell types. IL-13Rα2, a high affinity 
receptor for IL-13, exists in membrane bound and soluble forms. It has been 












Furthermore, it inhibits IL-13 dependent symptoms in experimental asthma 
and might provide a negative feedback mechanism in allergic diseases.160 
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Figure 5: IL-4 and IL-13 receptor complexes.  IL-4 interacts with type I and II receptor 
complexes. IL-13 interacts with the type II receptor complex and with IL-13Rα2. Type I and 




1.2.7 IL-4Rα in allergies  and asthma 
 
Many cells, directly involved in the pathology of allergic asthma are 
expressing functional IL-4 and IL-13 receptors.88 The importance of these 
cytokines in disease development gives the IL-4Rα chain a central role in the 
induction of allergic symptoms. Blocking of IL-4Rα impaired the development 
of AHR and airway eosinophilia in experimental allergic asthma 161, 162 and IL-












protected from the development of goblet cell hyperplasia, eosinophilic airway 
inflammation and allergen specific IgE production.86 Instead, IL-4Rα deficient 
animals show antigen specific Th1 type cytokine and antibody responses and 
airway inflammation, characterised by high neutrophils numbers.  However, 
IL-13 and IL-5 dependent development of AHR and specific IgE in IL-4Rα 
deficient mice has been demonstrated.163-165 
 
IL-4Rα signals contribute to the development of Th2 cells, but the contribution 
of Th2 cells in allergy development needs to be defined. These cells are 
associated with allergic asthma and their production of Th2 cytokines is 
thought to be critical for disease development. Several studies are supporting 
this concept as CD4+ T cells are necessary for development of airway 
eosinophilia and AHR 124 and allergen specific Th2 cells are able to induce 
allergic airway symptoms.166, 167 However, a recent study suggested that Th2 
cell derived IL-4 and IL-13 may not be necessary for the development of 
allergic symptoms and that the main source of IL-4 and IL-13 in allergy might 
be non-eosinophil cells of the innate immune system.168  
 
Cells of the innate immune system, such as basophiles and mast cells, are 
critically involved in the disease pathology of allergic asthma and are 
important producers of Th2 cytokines.103 These cells express IL-4Rα 88 and 
IL-4 and IL-13 responsiveness may contribute to the development of a Th2 
type immune response.169, 170  
 
Development of so called alternatively activated macrophages (AAM) is 
induced by IL-4 and IL-13 signals through IL-4Rα.141 AAM are found in high 
numbers in experimental and human asthma and produce several allergy 
associated molecules, such as arginase and Ym1.141 Some studies suggested 
a role of AAM in eosinophil recruitment 171 and contributions to tissue 
remodelling in the chronic phase of allergic asthma.141 However, a functional 













Airway hyperresponsiveness is caused by contraction of airway smooth 
muscle cells (ASMC) to a specific or unspecific stimulus and it is apparent that 
these cells play an important role in the onset of asthma. Several in vitro 
studies, showed clear evidence for a direct involvement of the IL-4Rα on 
smooth muscle cells in this process.145 Stimulation of cultured ASMC with IL-4 
or IL-13 increased hypercontractility in a STAT 6 dependent manner.172-174 
Furthermore, in vitro data suggested that IL-4Rα signalling on ASMC 
contributes to airway inflammation by release of inflammatory cytokines, such 
as eotaxin.175, 176 It is currently believed that IL-4Rα responses of ASMC 
contribute significantly to the onset of allergic asthma, but these effects still 
need to be demonstrated in vivo. 
 
Allergic asthma is characterised by a complex system of different overlapping 
symptoms, involving a large number of IL-4Rα expressing cell types. Although 
the general importance of the IL-4Rα in disease development is well 
established, its cell type specific functions often remain elusive. For many 
cells involved in disease development the role of IL-Rα is controversial or not 
understood and several open questions remain.  
 
The development of the loxP/Cre system for cell specific gene targeting 
enabled development of mouse models that allow investigation of gene 
defects on a cellular level.177 In transgenic mice, Cre recombinase expression 
under control of a cell type specific promotor induces homologous 
recombination between two loxP sites that flank essential exons of a gene of 
interest, leading to the disruption of the gene.178 This technology was used to 
generate several transgenic mouse strains with cell type specific disruptions 
of the il4ra gene on a Balb/c genetic background.179-183 Exons seven through 
nine of the il4ra gene are excised in target cells, whereas all other cell types 
carry a functional il4ra gene with a silent mutation, due to the insertion of loxP 
sites into intron regions (IL-4Rαlox/lox mice). The efficiency of gene deletion 
was enhanced by generation of hemizygous mice carrying one loxp il4ra allele 












demonstrated a Balb/c phenotype for hemizygous IL-4Rα-/lox mice and these 
mice were used as wild type control animals in this study. 180, 183  
 
Mice with cell type specific disruption of the il4ra gene allow the investigation 
of cell type specific roles of the IL-4Rα in disease development. This 
approach was successfully used to demonstrate that IL-4Rα signalling in clara 
cells, goblet cell precursors in the airway epithelium, is required for allergen-
induced mucus production in experimental asthma.181 Disruption of the il4ra 
gene in clara cells had no effect on other allergic symptoms. 
 
This was the first study that demonstrated that IL-4Rα signalling in a single 
cell type was sufficient for the development of a major symptom of allergic 
airway disease. Generation of transgenic mice with cell type specific 
disruptions in the il4ra gene in macrophages 180 and smooth muscle cells 183 
are an excellent tool for defining a role for specific contributions of IL-4Rα 

















































Figure 6. Potential roles for IL-4R α in  the development of allergic asthma.  IL-4Rα is 
expressed on various cell types associated with the early phase of allergic asthma. Cell 
specific contributions of IL-4Rα signals to the disease pathology remain to be defined. Th, T 
helper cell; AAM, alternatively activated macrophage; ASMC, airway smooth muscle cell. 















1.3 Objectives of this project 
 
Aim of the present study was to investigate influences of different routes of 
sensitisation on the development of allergic airway disease with focus on the 
role of IL-4Rα in mouse models. 
 
Mouse models of allergic diseases have demonstrated that the route of 
sensitisation is influencing allergic symptoms and underlying immune 
responses.59, 92 The fish parasite Anisakis can induce allergic reactions in 
humans and accidental infection has been considered as an important way of 
sensitisation.56 Furthermore, studies from our laboratory and others have 
shown that exposure to aerosolised allergens from Anisakis pegreffii 
increases the risk of developing allergic airway symptoms.59, 60 Currently it is 
not clear if different exposure routes to Anisakis affect the development of 
allergic asthma and if they have an influence on the immune response. To 
address these questions, the present study investigated immune responses 
and allergic symptoms after Anisakis live infection and nasal allergen 
sensitisation in a mouse model of allergic airway disease.  
A central role in the development of allergic diseases plays IL-4Rα. 
Contribution of IL-4Rα after live infection or nasal sensitisation with Anisakis 
was investigated by comparing IL-4Rα deficient mice with wild type Balb/c 
mice.  
 
IL-4Rα is expressed on a variety of cells involved in allergic asthma but its cell 
specific contributions to disease development remain to be defined. 
Contraction of airway smooth muscle cells (ASMC) plays a central role in 
asthma pathology. From in vitro studies, it is currently believed that signals of 
IL-4Rα on ASMC contribute to airway hyperresponsiveness and airway 
inflammation.145 To test this hypothesis in vivo, SMCcreIL-4Ra-/lox mice, 183 
which are deficient in ASMC IL-4Rα, were investigated in a mouse model of 













AAM are a feature of allergic asthma in human studies and mouse models 141 
but no functional role in disease development could be defined so far. 
LysMcreIL-4Rα-/lox mice have a cell type specific disruption if the il4ra gene in 
macrophages and neutrophils and show impaired AAM development.180  
These mice were used in a model of ovalbumin induced allergic airway 
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The Route of Sensitization to Anisakis pegreffii 































2 The Route of Sensitization to Anisakis pegreffii 






The fish parasite Anisakis pegreffii is able to cause allergies after accidental 
infection of humans and in the occupational environment. The present study 
examines differences in the immune response and development of allergic 
asthma that are due to different routes of sensitisation to Anisakis allergens. 
 
Methods 
Wild type and IL-4Rα deficient mice were either sensitized by infection with 
live larvae of Anisakis pegreffii or by intranasal administration of Anisakis 
extract. Allergic airway responses were induced by intranasal challenge with 
Anisakis pegreffii extract and mice were analysed for airway 
hyperresponsiveness, airway inflammation, allergen specific antibody 
production, Th2 type cytokine responses and lung pathology. 
 
Results  
Mice developed allergic asthma after infection with live Anisakis larvae. 
Airway hyperresponsiveness was independent of IL-4Rα but expression of 
this receptor was crucial for eosinophilic airway inflammation and goblet cell 
hyperplasia.  
Nasal sensitisation with Anisakis protein extract induced typical symptoms of 
allergic asthma in Balb/c mice. Airway hyperresponsiveness, eosinophilic 
airway inflammation and goblet cell hyperplasia were dependent on IL-4Rα 
















This study showed that the route of sensitisation influences the outcome of 
Anisakis pegreffii induced allergic asthma and its underlying immune 
response. Sensitisation by infection with live larvae and inhalation of proteins 
can be important routes of sensitisation of humans to Anisakis and different 





Anisakis spp. are nematode parasites of marine mammals with a worldwide 
distribution and a complex live cycle which includes several intermediate 
hosts. L3 larvae of Anisakis pegreffii are frequently found in commercially 
important sea fish designated for human consumption and infection levels in 
South African fish populations reach 95-100%.1 Most parasites live in the 
visceral cavity of infected fish but occasionally a few individuals migrate into 
the muscle of the host. The prevalence of Anisakis worms in fish fillets varies 
considerably depending on the fish species2. Eating contaminated fish can 
cause health problems in humans as infection with L3 larvae may occur after 
consumption of raw or undercooked fish infested with the parasite. Common 
sources of infection are raw, smoked or pickled fish and most cases are 
reported from countries like Japan and Spain where these dishes are 
frequently consumed.3-5 After infection the larva invades the gastric or 
intestinal mucosa by secreting proteases,6 causing painful tissue damage and 
inflammatory reactions. The disease caused by infection with live larvae is 
called gastric or intestinal anisakiasis. Symptoms such as nausea, abdominal 
pain and vomiting may only appear within 12h after ingestion which is why 
they are often not related to fish consumption.7 Acute anisakiasis often 
remains undiagnosed as clinical features of infection are similar to gastric 
ulcer or appendicitis.8 Endoscopic examination is the best way of diagnosis 9 
and symptoms disappear after removal of the larvae.7 The health risk of 
Anisakis infection has been recognised and the European Union and United 












uncooked fish designated for consumption in order to prevent development of 
acute or chronic anisakiasis.3  
 
Cases of hypersensitivity reactions to Anisakis, so called gastroallergic 
anisakiasis have been reported in patients infected with Anisakis.10, 11 
Symptoms range from urticaria and angioedema7 to live-threatening 
anaphylaxis.11, 12 Hypersensitivity symptoms are mediated by Anisakis-
specific IgE as opposed to symptoms of gastric anisakiasis and usually 
appear between 1-2h after fish consumption.3 Allergic reactions to Anisakis 
are thought to be a memory response to a previous infection after a second 
encounter with Anisakis antigens.13 It is still controversial whether 
consumption of fish contaminated with Anisakis proteins is sufficient for 
sensitisation and development of allergic reactions or if this reactions require 
the presence of live larvae.3 Sensitised patients were symptom free after a 
frozen fish diet or oral challenges with Anisakis protein preparations14-16 and it 
was concluded that the live larvae is necessary for the development of 
hypersensitivity reactions. Nevertheless, allergic reactions to Anisakis have 
also been reported after consumption of well cooked or previously frozen fish 
indicating that proteins of the worm might be sufficient for sensitisation and 
hypersensitivity reactions.17-21 Several allergens of Anisakis are heat stable 
and pepsin resistant 22, 23 and cooking might therefore not destroy their 
allergenic capacities.24  In countries with high fish consumption a large 
proportion of cases of food allergies and anaphylactic reactions can be due to 
Anisakis. In Spain, Anisakis is one of the most common hidden food 
allergens.25  
 
Immunological mechanisms behind human anisakiasis or Anisakis allergies 
remain to be defined. Penetration of gastric or intestinal tissues evokes an 
inflammatory response with eosinophilic infiltrates of the gastrointestinal wall 
around the parasite and blood eosinophilia.26-28 Anisakis protein extract has 
been shown to be chemotactic for eosinophils but not neutrophils.29 
Eosinophils and lymphocytes are present at the site of inflammation caused 
by Anisakis infection and expression of IL-4 and IL-5 but no detectable IFN-γ 












proliferation of blood lymphocytes from patients was stimulated by Anisakis 
antigen.8 These results show characteristic features of a Th2 type immune 
response as typically seen in nematode infections and allergic reactions. In an 
experimental mouse model, infection with Anisakis induced a IL-4 dependent 
Th2 type immune response with increased levels of specific IgE and IgG130 
which is comparable to the situation in human patients.8, 31 Subsequent oral 
challenge of sensitised mice with Anisakis extract induced mast cell 
degranulation, histamine release and symptoms of food allergy. 
 
Whereas urticaria, angioedema and anaphylaxis are the most common 
symptoms of Anisakis allergy several studies also have reported respiratory 
manifestations of the disease. In food allergic patients a correlation between 
asthmatic symptoms and Anisakis sensitisation was found in a Spanish 
study.32 Respiratory symptoms are common features of food allergies 33, 34 
and patients with sensitisation to Anisakis might be at risk of developing 
allergic asthma after consumption of contaminated fish. A recent study from 
our group supported this possibility. In an experimental mouse model for 
Anisakis induced food allergy it was shown that mice develop symptoms of 
allergic airway disease after infection and intragastric challenge with 
Anisakis.30 Cases of occupational conjunctivitis 35 and high prevalence of 
sensitisation in fishermen and fish mongers 36 suggested that Anisakis is also 
an airborne allergen causing symptoms after inhalation. A Spanish study 
reported the first case of occupational asthma caused by Anisakis in workers 
exposed to contaminated fish meal or fish.37 A recent study from our group 
found a correlation between fish consumption, Anisakis sensitisation and 
airway hyperresponsiveness in fish factory workers in South Africa30,38-40. 
Other case reports showed occupational asthma due to Anisakis after 
handling frozen fish,41 fish meal42 or exposure to fumes from cooked fish.43 
Whereas live infection with Anisakis seems to be the most important way for 
the development of food allergies, sensitization by inhalation of Anisakis 
proteins might be important in occupational allergies. 
Mouse models are frequently used to study underlying mechanisms of allergic 
diseases. Immune responses that finally lead to the development of allergic 












conditions. Mouse models of allergic asthma show similarities to the human 
disease such as airway hyperresponsiveness, goblet cell hyperplasia and 
airway inflammation.44,45 The use of genetically modified mice allows 
investigation of the role of specific genes in disease development.  
 
In sensitised mice the development of allergic asthma after oral challenge with 
Anisakis allergens was dependent on IL-4 and IL-13 30 but immunological 
mechanisms of Anisakis induced allergic asthma after inhalation of the 
allergens have not been investigated yet. The aim of this study was to 
compare the impact of two different routes of sensitisation to Anisakis pegreffii 
on the outcome of experimental allergic asthma. Mice were either infected 
intraperitoneally with live Anisakis larvae or exposed to Anisakis extract via 
the nose. The effect on allergic sensitisation was investigated by comparing 
specific antibody and cytokine responses. Allergic asthma was induced by 
intranasal challenge with Anisakis extract and airway inflammation, airway 
hyperresponsiveness, lung pathology and mucus production was compared 
between the two sensitisation groups. From mouse models of allergic 
diseases it is known that the development of allergic symptoms is dependent 
on the cytokines IL-4 and IL-13 and their common receptor IL-4Rα,46, 47 
therefore the development of allergic asthma in response to Anisakis was 



























The experiments were performed with 6-8 weeks old female wild type Balb/c 
mice or IL-4Rα-/- mice on a Balb/c genetic background.48 Animals were 
housed in the animal unit of the University of Cape Town under specific 
pathogen free barrier conditions using individually ventilated cages. All 
experiments were approved by the Research Animal Ethics Committee of the 
University of Cape Town. 
 
2.3.2 Anisakis larvae 
 
L3 stage larvae of Anisakis pegreffii were collected from the viscera of 
parasitized snoek (Thyrsites atun) and washed in 4% acetic acid and 
phosphate-buffered saline (PBS). Larvae were frozen at -80ºC for protein 
extract or stored live at 4ºC in Iscove’s Modified Dulbecco’s medium (IMDM) 
containing 100µg/ml penicillin and 100µg/ml streptomycin (Gibco, UK). Before 
use in live infections, larvae were re-washed in sterile PBS. 
 
2.3.3 Anisakis extract 
 
Frozen Anisakis larvae were homogenized in PBS and then sonicated with a 
MicrosonTM ultrasonic cell disrupter (Misonix, USA). The extract was 
centrifuged for 15min at 20000rcf and filter-sterilized through a 0.20µm filter 
(Sartorius, Germany). Protein concentration was measured by BCA test 
(Pierce, USA) according to manufacturer’s instructions. Anisakis extract was 













2.3.4 Anisakis live infection and intranasal challenge 
 
Mice were anaesthetized with 200µl of ketamine (Centaur Labs, South 
Africa)/xylazine (Bayer, South Africa) anaesthetic, and then injected 
intraperitoneal with two larvae in 1ml PBS at day 0 and day 21 using a 12 
gauge needle (Identipet, South Africa). On days 42, 43 and 44 mice were 
anaesthetised with 200µl Ketamine (Centaur Labs, South Africa)/ Xylazine 
(Bayer, South Africa) and challenged with 0.1mg Anisakis protein extract in 
50µl PBS by intranasal administration. PBS control groups were treated 
identically except Anisakis larvae were missing in the solutions. Mice were 
killed and analysed on day 46. 
 
2.3.5 Nasal allergen sensitisation and intranasal challenge 
 
Mice were anaesthetized with 200µl Ketamine (Centaur Labs, South Africa)/ 
Xylazine (Bayer, South Africa) and sensitised on day 0, 7 and 14 with 50µg 
Anisakis protein extract in 10µl PBS/ 1.3% aluminium hydroxide (Sigma) by 
intranasal administration. On days 21, 22 and 23 mice were anaesthetised 
with 200µl Ketamine (Centaur Labs, South Africa)/ Xylazine (Bayer, South 
Africa) and challenged with 0.1mg Anisakis extract in 50µl PBS by intranasal 
administration. PBS control groups were treated identically except Anisakis 
was missing in the solutions. Mice were killed and analysed on day 24 or day 
25 if airway if airway hyperresponsiveness was measured. 
 
2.3.6 Airway Hyperresponsiveness 
 
Responsiveness to β-methacholine (Sigma) was assessed in conscious 
unrestrained mice using a whole body plethysmograph (emka Technologies, 
France) and analysed with iox2 software (emka Technologies, France). This 












computes enhanced pause (Penh) values, a dimensionless parameter 
calculated by the formula 
 
Penh= (expiratory time / relaxation time-1)    
  x (peak expiratory flow / peak inspiratory flow) 49  
 
Increasing duration of the late phase of expiration relative to its early phase 
and increasing pressure change during expiration relative to the pressure 
change during inspiration results in increasing Penh values.50 It has been 
shown previously that changes in Penh values correlate with changes in 
airway resistance in the Balb/c mouse strain under similar conditions to those 
used here.49, 51, 52 Individual mice were placed in plethysmograph chambers 
and baseline readings were measured for 5min before each exposure to 
increasing doses of aerosolised methacholine (0, 10, 20, 40 mg/ml 
methacholine in PBS). The responses were measured for 15 min after each 
nebulisation. Results are computed as average of first 5 min minus average of 
baseline reading. 
 
2.3.7 Serum antibodies 
 
Blood samples were taken by tail vein bleeding or directly from mice after 
killing and collected in plasma separator tubes (MicrotainerTM SST, BD, USA). 
Samples were centrifuged for 20min at 6000rcf and stored at -80ºC. Anisakis 
specific antibodies were measured in blood serum by endpoint titration ELISA. 
For antigen specific antibody-ELISA 96 well plates (Maxisorp, Nunc, 
Denmark) were coated overnight with 50µl Anisakis extract in PBS (5µg/ml for 
IgG1, IgG2a, IgG2b or 100µg/ml for IgE). For total IgE ELISA plates were 
coated with anti-mouse IgE antibody (clone 84.1C, 1/1000 dilution). Plates 
were blocked for 1h at 37ºC with 200µl 2% fat free milk powder in PBS. Serial 
dilutions of serum samples in 50µl PBS/ 0.1% BSA were added to the wells 
and plates were incubated over night at 4 ºC. Purified recombinant mouse IgE 
(BD, USA) was used as a standard for total IgE ELISA, at a starting     












mouse isotype specific antibodies (Southern Biotechnology, USA) at a 1/1000 
dilution in PBS/ 0.1% BSA were added to the wells and the plates were 
incubated for 3h at 37ºC. Subsequently plates were incubated with 50µl p-
nitrophenylphosphate (Fluka, Switzerland) and colour reaction was stopped 
with 50µl 1M NaOH. Absorption was measured at 405nm with 492nm as 
reference wave length using a VersaMax plate reader (Molecular devices, 
USA). Plates were washed 4x with 200µl per well after each incubation step.  
 
2.3.8 Western Blot Analysis 
 
Anisakis extract was separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE). A 10% separating gel (14.5x11cm) was prepared first and left to 
polymerize for 30 minutes. The stacking gel was poured onto the separating 
gel and a 1-well comb (+1 reference well for molecular weight marker) was 
added. 200µg protein in 160µl TBS and 40µl 5xSDS-sample buffer was boiled 
for 5 min before being loaded onto the gel. 6µl Precision Plus Dual Color 
molecular weight marker (Bio-Rad, USA) was loaded into the reference well. 
Proteins were separated at 150V over a length of 8cm. After SDS-PAGE 
proteins were transferred onto a nitrocellulose membrane (Amersham, UK) for 
1h at 400mA. The membrane was blocked for 1h at RT in TBS/0.1% 
Tween/5% fat free milk powder before it was placed in a 21 lanes Western 
Blot Screening Device. 200µl serum samples were loaded per lane in a 1/100 
dilution in TBS and incubated for 3h (for IgG) or overnight (for IgE). Afterwards 
the membrane was washed 3x in TBS/0.1% Tween and incubated with 
horseradish peroxidase (HRP) labelled rat anti-mouse IgE (ε-chain specific, 
Southern Biotechnology, USA) for 3h. After 3x washing in TBS/ 0.1% Tween 
the Western blot was developed with 2ml ECL solution (Amersham, UK). 















2.3.9 Bronchoalveolar Lavage 
 
Mice were killed by CO2 asphyxiation and lungs were washed once with 1ml 
PBS through an 18G IV catheter (Braun, Germany). Recovered 
bronchoalveolar lavage (BAL) fluid of individual mice was centrifuged for 
10min at 400rcf and the cell pellet was resuspended in 0.5ml DMEM after. 
Total cell numbers in the BAL fluid were counted in trypan blue (SIGMA, 
Germany) stained aliquots using a haemocytometer. A maximum of 2x105 
cells in 200µl was centrifuged on a microscope slide at 800rpm for 5 min 
using a Cytospin centrifuge (Shandon, UK). The slides were air-dried and 
stained with a Rapidiff Stain Set (Clinical Diagnostics CC, South Africa). 
Differential cell counts for eosinophils, neutrophils, lymphocytes and 
macrophages were made at 400x magnification and at least 100 cells were 
counted per slide. 
 
2.3.10 In vitro restimulation of lymphocytes 
 
Lymphocytes were purified from lung draining lymph nodes for in vitro 
restimulation experiments. Lymph nodes were removed from the mice and 
pooled in DMEM/ 2% FCS for each experimental group. Lymph nodes were 
pressed through a 70µm cell strainer (BD, USA) and the single cell 
suspension was washed once with 10ml DMEM/ 2% FCS. The pellet was 
resuspended in 1ml of ice-cold red cell lysis buffer for 2-5 minutes on ice and 
cell lysis was stopped by adding 10ml DMEM/ 2% FCS. The cells were 
centrifuged at 300rcf for 5 minutes. 2x 105 lymphocytes per well were 
restimulated in U-bottom 96-well plates (Nunc, Denmark) with 100mg/ml 
















2.3.11 Cytokine ELISA 
 
Cytokine concentrations in the supernatant of in vitro restimulated 
lymphocytes were determined by ELISA. Plates (Maxisorp, Nunc, Denmark) 
were coated overnight with 50µl anti-IL-4 (clone 11B11), anti-IL-5 (BD, USA), 
anti-IL13 (R&D Systems, USA) or anti-IFNγ (clone AN18KL6) capture 
antibodies at 4ºC. Plates were blocked for 1h at 37ºC with 200µl 2% fat free 
milk powder in PBS. Samples or serial dilutions of recombinant cytokine 
standards (BD, USA) in 50µl PBS/ 0.1% BSA were added to the wells and 
plates were incubated overnight at 4 ºC. Biotinylated secondary antibodies 
were added and plates were incubated for 3h at 37ºC followed by horseradish 
peroxidase (HRP) labelled streptavidin for 1h at 37ºC. Subsequently plates 
were incubated with 50µl TMB Peroxidase Substrate (KPL, USA) and colour 
reaction was stopped with 50µl 2M H2SO4. Absorption was measured at 
450nm with 540nm as reference wave length using a VersaMax plate reader 
(Molecular devices, USA). Plates were washed 4x with 200µl of wash buffer 
per well after each incubation step.  
 
2.3.12 EPO assay and MMCP-1 ELISA 
 
Lung tissue was homogenized in Tris/ NP-40 buffer and then centrifuged for 
20 minutes at 14000rpm for mouse mast cell protease-1 (mMCP-1) ELISA 
and Eosinophil Peroxidase (EPO) assay. A colorimetric assay for EPO was 
used to quantify eosinophils in the lung tissue. 50 µl of the substrate solution 
consisting of 16mM o-phenylenediamine (Sigma, Germany) in 100mM Tris-
HCl buffer pH 8.0 containing 0.1% Triton and 0.01% hydrogen peroxide was 
added to 50µl tissue sample (protein concentration 1mg/ml) and peroxidase 
standard (Sigma, Germany) in 96 well plates. The reaction was stopped after 
5 minutes with 50µl 2M H2SO4 and absorption was measured at 490nm. 
Mouse Mast Cell Protease concentrations were determined by ELISA 












2.3.13 Lung Histology and Immunohistochemistry 
 
Lung tissue was fixed in 4% Formaldehyde in PBS, embedded in paraffin and 
cut in 5-7µm sections. Sections were stained with Periodic acid-Schiff reagent 
(PAS) or haematoxylin and eosin (H&E).  
 
2.3.14 Statistical Analysis 
 
Values are given as mean ± SD and significant differences were determined 






2.4.1 Antibody responses after infection of mice with Anisakis 
larvae and nasal exposure to Anisakis extract 
 
Two new mouse models were used in the present study to investigate the 
influence of the route of sensitisation on the development of allergic airway 
disease in response to Anisakis pegreffii. In the first model mice were infected 
twice with live Anisakis larvae (Fig 1A) whereas in the second model mice 
were sensitised by nasal administration of Anisakis extract (Fig. 1B). In both 
models, mice were challenged after sensitisation intranasally with Anisakis 
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Figure 1. Live infection with Anisakis larvae or nasal sensitisation with Anisakis extract 
followed by intranasal challenge with Anisakis protein extract. Mice were infected 
intraperitoneally with 2 live Anisakis pegreffii larvae on day 0 and day 21 (A) or sensitised 
intranasally (i.n.) with 50µg Anisakis extract in 10µl PBS/ Alum on day 0, 7 and 14 (B). This 
was followed by 3 intranasal (i.n.) challenges of anesthetized mice with 0.1mg Anisakis 
extract in 50µl PBS. Airway hyperresponsiveness (AHR) was measured one day before mice 
were sacificed for analysis. The PBS control group was treated identically except antigens 
were absent from the solutions. 
 
 
To compare antibody responses after repeated infection of mice with Anisakis 
larvae, specific antibody levels were determined by ELISA in Balb/c and IL-
4Rα-/- mice on days 21 and 45 post infection. Serum levels of Anisakis 
specific IgG1 and IgE, typical Th2 type antibodies, were significantly 
increased in infected Balb/c mice on day 21 post infection. Reinfection further 
elevated the serum antibody titres by day 45 (Fig. 2A). In accordance with the 
specific antibody response, total IgE concentrations were elevated after first 
infection and further increased after the second infection (Fig. 2B). IL-4Rα-/- 
mice produced specific IgG2a and IgG2b and to a lesser extent IgG1 and the 
concentrations of specific IgG were further increased by the second infection 
with Anisakis larvae (Fig. 2A). Specific and polyclonal IgE were not detected 






























































































































Figure 2. Repeated infection of mice with Anisakis larvae induces a strong specific 
antibody response. Balb/c and IL-4Rα-/- mice were infected with live Anisakis larvae on day 
0 and day 21. Serum concentrations of antigen specific IgE and IgG (A) and total IgE (B) were 
determined 3 weeks after each infection. Data represent the pool of two experiments +/-SD 
(*p<0.05; **p<0.01; ***p<0.001 vs. PBS control group). 
 
 
In contrast to the high antibody titres after infection with Anisakis, repeated 
nasal sensitisation and challenge only induced a weak specific IgG1 response 
in Balb/c mice (Fig. 3A). Concentrations of total IgE were not affected by 












concentrations was found in IL-4Rα-/- mice (Fig. 3A) and IgE could not be 
















IL-4Rα-/- Anisakis sens. Anisakis chall.
Balb/c Anisakis sens. PBS chall.
Balb/c Anisakis sens. Anisakis chall.
B
Balb/c PBS control
Balb/c Anisakis sens. Anisakis chall.
IL-4Rα-/- Anisakis sens. Anisakis chall.
























































Figure 3. Nasal sensitisation with Anisakis antigens does not induce systemic IgE but 
weak IgG1 antibody response. Balb/c and IL-4Rα-/- mice were intranasally sensitised and 
challenged with Anisakis extract Serum concentrations of antigen specific IgG (A) total IgE (B) 
were determined by ELISA. Data represent the pool of two experiments +/-SD (**p<0.01 vs. 














Anisakis specific IgE responses were compared by Western Blot analysis to 
identify Anisakis allergens (Fig. 4). IgE binding to Anisakis proteins was found 
only in the Balb/c strain but not in IL-4Rα-/- mice after live infection confirming 
the ELISA results where total IgE concentrations were only elevated in Balb/c 
mice. IgE antibodies against four allergens with the size of 35, 45, 70 and 73 
kDa were found in Balb/c mice. No Anisakis specific antibodies were detected 


















Figure 4. Infection with Anisakis larvae but not nasal sensitisation with Anisakis 
antigens induces IL-4Rα dependent IgE antibody response. Western blot analysis of 
serum from Balb/c mice or IL-4Rα-/- mice after Anisakis infection or nasal antigen sensitisation 
for Anisakis specific IgE antibody. (3 individual mice per group). 
 
 
2.4.2 Allergen specific cytokine Response after intranasal allergen 
challenge 
 
Development of allergic asthma is driven by Th2 cytokines especially IL-4, IL-
5 and IL-13. Therefore lymphocytes from lung draining lymph nodes were 
analyzed for cytokine production after in vitro restimulation with Anisakis 
extract. In Balb/c mice infected with Anisakis larvae, intranasal antigen 
challenge induced an antigen specific Th2 cytokine response with increased 












levels in infected and PBS challenged mice were not elevated when 
compared to the uninfected control group. IL-4Rα-/- mice responded with a 
predominant Th1 cytokine response to intranasal challenge after infection as 
reflected by highly increased IFN-γ only slightly elevated concentrations of the 
Th2 cytokines IL-4 and IL-5, and no detectable IL-13 (Fig. 5A).  
A similar response was found after nasal sensitisation with Anisakis extract 
(Fig. 5B). Sensitisation to Anisakis extract alone did not induce a Th2 
response in the lung draining lymph nodes. After intranasal challenge cells in 
lung draining lymph nodes of sensitized Balb/c mice produced Th2 cytokines 
including IL-4, IL-5 and IL-13, but not IFN-γ whereas IL-4Rα-/- mice produced 
































































































































































Figure 5. Balb/c mice develop an IL-4Rα dependent TH2 type cytokine response to 
Anisakis antigens.  Lymphocytes were isolated from lung draining lymph nodes of mice  
challenged with Anisakis antigens  after sensitisation by (A) live infection with Anisakis larvae 
or (B) nasal administration of Anisakis extract. Cytokine secretion of pooled lymphocytes in 
vitro stimulated with Anisakis extract or culture medium alone was measured by ELISA in 
triplicates. Data represent one of two experiments +/-SD (*p<0.05; **p<0.01; ***p<0.001 













2.4.3 Airway hyperresponsiveness after intranasal allergen 
challenge  
 
Airway hyperresponsiveness (AHR) to non-specific bronchoconstrictors is 
characteristic of allergic asthma. After Anisakis infection and challenge or 
intranasal sensitisation and challenge mice were exposed to increasing doses 
of aerosolized β-methacholine and airway hyperresponsiveness was 
determined by whole body plethysmography. Intranasal challenges induced 
airway hyperresponsiveness in Balb/c mice after infection with Anisakis larvae 
(Fig. 6A) and after nasal sensitisation with Anisakis extract (Fig. 6B) as 
reflected in increased Penh values after challenge with 20 and 40mg/ml β-
methacholine. Interestingly AHR persisted in IL-4Rα-/- mice only in the model 
of Anisakis live infection (Fig. 6A). AHR after challenge with 20mg/ml β-
methacholine was higher in IL-4Rα-/- mice compared to Balb/c mice and an 
equal response was found after 40mg/ml challenge. In the intranasal 
sensitisation/ challenge model development of AHR was IL-4Rα dependent 
and Penh values were higher for Balb/c mice compared to IL-4Rα mice (Fig. 
6B). Sensitisation alone had no significant effect AHR as the response to β-
methacholine was not significantly different between the PBS control group 
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Figure 6. Airway hyperresponsiveness after intranasal challenge with Anisakis 
antigens is IL4Rα dependent after nasal sensitisation to Anisakis but not after live 
infection. Airway response to increasing concentrations of aerosolised methacholine (MCh) 
was measured by whole body plethysmography 1d after final allergen challenge in 
unrestrained mice sensitised by (A) live infection with Anisakis larvae or (B) nasal 
administration of Anisakis extract. Penh: Average of Penh values of the first 5min after MCh 
challenge. Data represent pool of two experiments +/-SD (*p<0.05; **p<0.01; ***p<0.001 vs. 













2.4.4 Recruitment of inflammatory cells to the lungs of allergen 
challenged mice 
 
In allergic asthma bronchi and alveoli are infiltrated by inflammatory cells with 
eosinophils being the characteristic cell type. Total numbers of inflammatory 
cells in the bronchoalveolar lavage of Anisakis challenged Balb/c and IL-4Rα-/- 
mice were significantly elevated above the PBS control groups in both models 
of Anisakis sensitisation (Fig. 7A). In the live infection model the total cell 
number in Balb/c mice was significantly higher than in IL-4Rα-/- mice (7.3 x105 
vs. 3.7 x105). Differential cell counts revealed that the main cell type infiltrating 
the BAL in Balb/c mice was eosinophils whereas in IL-4Rα-/- mice it was 
neutrophils (Fig. 7B). The total number of eosinophils found in Balb/c mice 
was double the number of neutrophils found in IL4Rα-/- mice explaining the 
difference in total cell numbers between the two mouse groups. Number of 
lymphocytes increased slightly but not significantly and total number of 
macrophages did not change after allergen challenge. No differences in 
numbers of macrophages and lymphocytes in the BAL were detected between 
Balb/c and IL-4Rα-/- mice.  
In the nasal sensitisation model no differences of total cell numbers was found 
between Balb/c and IL-4Rα-/- mice (Fig. 7A). As in the infection model the 
main cell type infiltrating the BAL in Balb/c mice was eosinophils whereas in 
IL-4Rα-/- mice it was neutrophils (Fig.7B). The eosinophil number in Balb/c 
was equal to the number of neutrophils in IL-4Rα-/- mice.  Number of 
lymphocytes increased slightly but not significantly in both mouse strains and 
numbers of lymphocytes in the BAL were equal in both mouse strains. Total 
























































































































Figure 7. Lungs of sensitised  mice are infiltrated by inflammatory cells after intranasal 
challenge with Anisakis antigens. Total cell numbers (A) and cellular composition (B) in 
BAL fluid was determined after challenge of sensitised mice with Anisakis extract. Data 
represent pool of two experiments for each sensitisation protocol+/-SD (*p<0.05; 













2.4.5 Lung pathology after airway challenge with Anisakis extract 
 
During allergic airway reactions, inflammatory cells infiltrate the lung tissue 
around blood vessels and airways. PBS sensitisation and challenge (Fig. 8A, 
E) and live infection and nasal sensitisation alone (Fig. 8B, F) failed to induce 
infiltration of the lungs by inflammatory cells. After intranasal challenge with 
Anisakis extract Balb/c mice (Fig. 8C, G) and IL-4Rα-/- mice (Fig. 8D, H) 
showed perivascular and peribronchial inflammation in both models of 
Anisakis sensitisation.  
Hyperplasia of mucus producing goblet cells in the lungs is a characteristic of 
allergic asthma. PBS sensitised and challenged mice showed no goblet cell 
hyperplasia (Fig. 8A, E). Histological examination of PAS stained lungs of 
Balb/c mice challenged with Anisakis protein extract after infection or 
intranasal challenge showed similar severity of goblet cell hyperplasia (Fig. 
8C, G) whereas Anisakis infection or antigen sensitisation alone did not 
induce increased mucus production (Fig. 8B, F). Mucus production was 
dependent on IL-4/ IL-13 signals as goblet cell hyperplasia was absent in IL-
4Rα-/- mice (Fig. 8D, H). 
H&E staining of lung sections showed high numbers of eosinophils present in 
the inflammatory cell infiltrate in Balb/c after Anisakis infection and nasal 
sensitisation (Fig. 9C, G). In IL4Rα-/- mice airway inflammation was present 
but without the eosinophilia seen in Balb/c mice (Fig. 9D, H). Airway 
eosinophilia was not found in PBS control mice (Fig. 9A, E), and after nasal 

















































Figure 8. Goblet cell hyperplasia is induced after intranasal challenge with Anisakis 
antigens in Balb/c but not IL-4Rα-/- mice after live infection with Anisakis larvae and 
nasal sensitisation with Anisakis extract. Histology sections of lungs were stained with 
periodic acid Schiff (PAS) to visualise mucus producing goblet cells in the airway epithelium 









































Figure 9. Eosinophilic airway inflammation after intranasal challenge with Anisakis 
antigens is dependent on IL-4Rα expression. Histology sections of lungs were stained with 
hematoxylin and eosin (H&E) to visualise infiltrating eosinophils (arrows). B: bronchiole; 400x 



















In the human context of Anisakis allergies, live infection seems to be the most 
common way of sensitization11, 53 whereas sensitization by inhaling Anisakis 
proteins might be predominantly important for sensitisation in the occupational 
environment.30, 35, 37 The aim of this study was to investigate whether different 
routes of sensitization to Anisakis pegreffii can influence the outcome of 
experimental allergic asthma and underlying immune responses. Two new 
mouse models of allergic asthma were established for this study in order to 
address this question. 
 
A mouse model of infection with live Anisakis pegreffii larvae was compared to 
a model of sensitization to Anisakis extract via the nasal route. After 
sensitization mice were challenged intranasally with Anisakis proteins to 
induce allergic responses in the airways. The identical method of allergen 
challenge enabled the investigation of differences in the pathology of the 
disease that were due to different routes of sensitization. Furthermore, the 
contribution of signalling through IL-4Rα, an important receptor in the 
regulation of allergic asthma in mouse models and the human disease,54 was 
taken into account by comparing wild type Balb/c mice with IL-4Rα-/- mice. 
This study with its focus on allergic airway responses in Anisakis allergies is in 
context of previous work in our research group where immune responses after 
Anisakis infection and gastric allergen exposure were investigated. In the 
previous study infection with Anisakis larvae induced a Th2 type immune 
response and IL-4Rα dependent food-allergic symptoms.30 
 
Comparison of signs of allergic asthma revealed that allergic airway disease 
was induced after live infection and nasal sensitization. Wild type Balb/c mice 
developed airway hyperresponsiveness, eosinophilic airway inflammation and 
hyperplasia of mucus producing goblet cells after challenge with Anisakis 
proteins. Onset of eosinophilic airway inflammation and goblet cell hyperplasia 
was IL-4Rα dependent as mice deficient for the receptor were protected 












models which showed critical involvement of this receptor and its ligand IL-13 
for allergen induced mucus production.55, 56 Development of airway 
hyperresponsiveness in IL-4Rα-/- mice was dependent on the route of 
sensitisation as it was only observed after infection with live Anisakis larvae 
but not after nasal sensitisation. AHR in these mice came as a surprise as 
studies in mouse models of allergic asthma have shown a critical role for IL-
4Rα and IL-13 in the development of airway hyperresponsiveness.46, 47 
However other studies have suggested IL-4Rα independent mechanisms of 
AHR in murine models of ovalbumin induced allergic asthma.57-59 The nature 
of this mechanism has not been defined yet but it was suggested that IL-5 and 
IL-13 are essential for IL-4Rα independent AHR.58 Whereas IL-5 was 
produced after live infection with Anisakis, no IL-13 production was found in 
lung draining lymph nodes of IL-4Rα-/- mice and the mechanism behind the 
development of AHR remains elusive. Differences between live infection and 
sensitisation with Anisakis extract include the exposure of the mice to the 
parasite over a long period (up to 14 days) and the in vivo secretion of 
proteins by the worm which are absent in the extract. These differences might 
be responsible for AHR development in IL-4Rα-/- mice after live infection but 
not after nasal sensitisation.  
Airway inflammation in Balb/c mice showed typical signs of an allergic 
response such as eosinophil infiltrations around the airways and elevated 
eosinophil numbers in the bronchoalveolar lavage fluid. Comparing numbers 
of eosinophils in the BAL between the two sensitization groups revealed that 
live infection induced stronger eosinophilia than nasal sensitisation. Infection 
with Anisakis is accompanied by blood and tissue eosinophilia26-28 which can 
explain the presence of high numbers of eosinophils in the allergic lung. 
Anisakis extract has been described to be chemotactic for eosinophils29 but 
might be not as efficient as in recruiting eosinopils as the live worm. Another 
reason might be lower production of IL-5, important for eosinophil 
differentiation and migration, in the local lymph nodes after nasal sensitisation 













After live infection, wild type and IL-4Rα-/- mice developed a strong IgG 
response against Anisakis antigens. This response was moderate three 
weeks after the first infection but a strong memory response was induced by 
reinfection and antibody levels increased substantially. In wild type mice this 
was the case for the type 2 antibodies IgG1 and IgE. IL-4Rα-/- mice on the 
other hand showed a mixed type 1/ type 2 antibody responses and the 
predominant antibody isotypes were IgG 2a and IgG2b, typically associated 
with Th1/ type 1 immune responses, but also the type 2 antibody IgG1. IgE 
could not be detected in these mice. A different situation was found after nasal 
sensitization where Anisakis specific antibodies were barley detectable 
despite the development of asthmatic symptoms. Balb/c mice produced low 
amounts of specific IgG1 with concentrations about 1000x lower compared to 
live infection and no IgE antibodies were found. Allergic airway symptoms in 
the absence of IgE have been described in murine models for aerosolised 
allergens 60, 61 and in human patients with asthma.62, 63 Patients with non-IgE 
mediated asthma can develop respiratory symptoms in the absence of 
allergen specific IgE antibodies but show elevated IL-4, IL-5 and IL-13 
levels.64-66  
 
In contrast to the antibody response, cytokine production was not dependent 
on the route of allergen sensitization. Wild type mice developed an antigen 
specific Th2-type cytokine response in lung draining lymph nodes after nasal 
sensitisation and live infection. Cytokine responses in Balb/c mice were 
characterized by the production of IL-4, IL-5 and IL-13 but not IFN-γ after 
allergen challenge. The data from the nasal sensitization model suggests that 
differentiation of T cells into allergen specific Th2 cells was sufficient for the 
development of allergic airway symptoms in the absence of specific 
antibodies. This might be important for the diagnosis of Anisakis allergies 
which often relies on the identification of specific IgE67-69. IL-4Rα-/- mice 
showed a Th1 polarized response reflected by IFN-γ secretion, but did not 
develop allergic asthma after nasal sensitisation. The cytokine responses in 
both sensitization models were induced by the intranasal allergen challenge 












As described previously,70, 71 infection of mice with Anisakis larvae was 
temporary and no live or dead larvae were found three weeks after the second 
infection when mice were killed and analysed. Therefore all results described 
here for the live infection model as well as the nasal sensitization model 
represent a situation where no live parasite was present at the time of the 
onset of allergic airway symptoms. It is still debated whether the parasite has 
to be alive to induce allergic reactions 3 but in murine models at least, 
presence of Anisakis proteins appears be sufficient for the development of 
allergic reactions. This is in agreement with other studies of mouse models 30 
and observations in humans.17, 19  
 
This is the first study that specifically investigates the immune response in 
Anisakis pegreffii induced allergic asthma by using animal models. 
Development of airway symptoms after Anisakis live infection followed by 
gastric allergen challenge has been described previously and the present 
study shows that allergic airway inflammation can also be induced by 
exposure of the respiratory system to Anisakis allergens. Two unexpected 
findings were of particular interest and might reflect typical features of 
Anisakis induced allergic airway disease. Depending on the route of 
sensitisation, mice developed signs of the disease in the absence of either 
allergen specific antibodies or an allergen specific TH2 type immune 
response. Wild type mice developed a Th2 type immune response and typical 
allergic symptoms after infection with Anisakis larvae. In IL-4Rα-/- mice, AHR 
could also be induced in an IL-4Rα and Th2 independent manner. 
Furthermore, it was shown that non-IgE mediated allergic asthma was 
induced after sensitization to Anisakis via the nasal route.  
 
The results presented here show new aspects of the immunology of Anisakis 
related allergies and demonstrate the importance of the route of sensitisation 
to Anisakis pegreffii for the development of allergic airway inflammation and 
its underlying immune response. Further studies are necessary to understand 
specific aspects of the disease in order to develop adequate diagnosis and 
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Smooth muscle IL-4Rα is not required for 



































3 Smooth muscle IL-4Rα is not required for 





Airflow in the lungs of patients with allergic asthma is impaired by excessive 
mucus production and airway smooth muscle contractions. Elevated levels of 
the cytokines IL-4 and IL-13 are associated with this pathology. In vitro studies 
have suggested that IL-4Rα signalling on smooth muscle cells is critical for 
airway inflammation and airway hyperresponsiveness. By using transgenic 
SMC-MHCcreIL-4Rα-/lox mice deficient for IL-4Rα in smooth muscle cells, in 
vivo effects of impaired IL-4Rα signalling in smooth muscle cells on the 
outcome of asthmatic disease were investigated for the first time.  
Methods 
Allergic asthma was introduced in mice by repeated sensitisation with 
ovalbumin/aluminium hydroxide on days 0, 7 and 14 followed by intranasal 
allergen challenge on days 21-23. Mice were investigated for the presence of 
airway hyperresponsiveness, airway inflammation, allergen specific antibody 
production, Th2 type cytokine responses and lung pathology. 
Results 
Airway inflammation, airway hyperresponsiveness, mucus production, Th2 
cytokine production and specific antibody responses were unaffected in SMC-
MHCcreIL-4Rα-/lox mice when compared to control animals. Unexpectedly, the 
impairment of IL-4Rα on smooth muscle cells had no effect on major 
aetiological markers of allergic asthma. 
Conclusion 
These findings suggest that IL-4Rα responsiveness in airway smooth muscle 
cells during the early phase of allergic asthma is not, as suggested, critical for 













3.2 Introduction  
 
Allergic asthma is characterised by airway obstruction, inflammation, and 
airway hyperresponsiveness (AHR). Patients with allergic asthma experience 
impaired respiratory air flow which is caused by a combination of increased 
airway mucus secretion and airway smooth muscle cell (ASMC) contraction in 
response to allergens.  
Immunologically it is established that T helper 2 (Th2) type cytokines, 
particularly IL-4 and IL-13 play an important role in asthma pathogenesis. 
Indeed, overexpression of these cytokines results in the development of 
asthmatic symptoms in murine models.1-4 Though IL-4 plays an important role 
in establishing Th2 responses,5, 6 IL-13 is the cytokine critical for driving actual 
asthmatic pathology. In the absence of IL-13, mucus production, AHR and 
airway inflammation are inhibited. Conversely, administration of recombinant 
IL-13 will induce these pathological features in non allergic mice.7, 8 Such IL-
13 driven effects occur irrespective of IL-4, nevertheless induction of a strong 
Th2 response and immunoglobulin class switching to IgE in mice requires IL-
4. These IL-4 and IL-13 mediated effects require signalling through 
heterodimeric receptors containing IL-4 receptor alpha (IL-4Rα). Mice 
deficient for IL-4Rα show protection from experimentally induced allergic 
asthma 9 and IL-4Rα antagonists abrogate the development of allergic airway 
symptoms.10  
It can be appreciated from this that an understanding of the role of IL-4Rα in 
specific cell types would enhance the understanding and treatment of asthma. 
Key cells involved in the onset and pathogenesis of asthma include T cells, B 
cells, epithelial and smooth muscle cells. To date the cell specific role of IL-
4Rα in allergy has only been described in vivo for epithelial cells. Here 
disrupted epithelial IL-4Rα signalling results in protection from AHR and 
airway mucus production.11  
In addition to immune and epithelial cells it is apparent that ASMC may also 
play an important role in the onset of asthma. Several in vitro studies have 
shown that IL-4 and IL-13 induce hypercontractility in smooth muscle cells in a 












hypercontractility response of ASMC to carbachol was attenuated in STAT6-/- 
mice. Use of anti-IL-4Rα antibodies also inhibited the contractile 
responsiveness of IgE sensitised ASMC to acetylcholine while pre-treatment 
with recombinant IL-13 enhanced contractile ability.15 In addition to effects on 
ASMC hypercontractility, human airway smooth muscle cells have been 
shown to release allergy associated chemokines, such as eotaxin 16-22 in 
response to IL-4 and/ or IL-13 in vitro. This IL-4/IL-13 driven eotaxin 
expression in ASMC can be inhibited by anti-IL4Rα antibodies 17 and 
antisense oligonucleotides to STAT6.23 
Owing to this substantial body of in vitro data, it was suggested that ASMC 
responsiveness to IL-4 and IL-13 contributes significantly to asthmatic 
pathology. To investigate the in vivo role of IL-4Rα signalling in smooth 
muscle cells we used a mouse model with smooth muscle cell specific 
disruption of the Il4ra gene (SM-MHCcreIL-4Rα-/lox mice). Recently 
characterised by our laboratory, SM-MHCcreIL-4Rα-/lox mice showed delayed 
mucus production, Th2 cytokine production and worm expulsion in a model of 
nematode infection.14 This was the first in vivo demonstration of the influence 
of IL-4Rα expression in smooth muscle cells on Th2 type immune responses 
of the host.  
The current study investigated for the first time the in vivo effect of IL-4Rα 
signalling in smooth muscle cells in a model of acute allergic asthma. The 
findings of several in vitro studies have suggested a role for IL-4/IL-13 
responsiveness in smooth muscle cells on the outcome of allergic airway 
disease, but surprisingly our results demonstrated that smooth muscle cell 
specific disruption of the IL-4Rα did not influence the acute phase of the 






















Generation and characterization of the SM-MHCcreIL-4Rα-/lox mice was 
described previously.14 SM-MHCcre  mice on a BALB/c background 24 were 
crossed with IL-4Rα-/- mice.25 In order to generate SM-MHCcreIL-4Rα-/lox mice 
they were then crossed with IL-4Rα-/lox mice 26 as the hemizygous IL-4Rα-/lox 
genotype increases the probability of Cre-mediated il4ra gene disruption. All 
mice were genotyped by PCR before the experiments to confirm smooth 
muscle cell-specific disruption of the il4ra gene. IL-4Rαlox/lox mice produce a 
functional IL-4Rα 26 and hemizygous IL-4Rα-/lox littermates were used as 
control groups. IL-4Rα-/- mice were used as global knock out controls for the 
IL-4Rα. Mice were housed in the animal unit of the University of Cape Town 
(UCT) under specific pathogen free conditions using individually ventilated 
cages. All work was approved by the UCT animal ethics committee. 
 
3.3.2 Isolation of smooth muscle cells from lung tissue 
 
Lungs were removed from mice, flushed with PBS, cut into small pieces and 
incubated for 3h at 37ºC in DMEM containing 1mg/ml Collagenase type II 
(SIGMA-ALDRICH, Germany). Digested tissue was put through a 70µm cell 
strainer and erythrocytes were lysed in a 0.15M NH4Cl buffer. For intracellular 
α-actin staining cells were incubated in Fixation/Permeabilization buffer 
(eBioscience, USA), blocked with 2% normal rat serum and 2% Fc block 
(2.4G2) and stained with  anti-smooth muscle α-actin FITC (Abcam, UK) or 
isotype control IgG2a FITC (BD, USA) antibodies. FITC positive cells were 














3.3.3 Analysis of IL-4Rα deletion efficiency by RT-PCR 
 
Genomic DNA was isolated from trachea and spleen tissue, CD4+ 
lymphocytes and α-actin sorted lung cells of SM-MHCcreIL-4Rα-/lox, IL-4Rα-/lox 
and IL-4Rα-/- mice. The copy numbers of IL-4Rα exon 5 and IL4-Rα exon 8 
were determined using a Roche Lightcycler (Roche, Germany) and 
amplification was monitored using SYBR GreenI. Cloned IL-4Rα exon 5 and 
exon 8 DNA was used to prepare a standard curve. Primers: exon 5 forward 
5’AACCTGGGAAGTTGTG 3’, exon 5 reverse 5’ CACAGTTCCATCTGGTAT 
3’, exon 8 forward 5’GTACAGCGCACATTGTTTTT 3’ and exon 8 reverse 5’ 
CTCGGCGCACTGACCCATCT 3’. 
 
3.3.4 Nippostrongulus Brasiliensis infection of mice 
 
Mice were infected with 750 N.brasiliensis L3 larvae as described previously 
and lung tissue was analysed at days 7 and 10 post infection. 14 
3.3.5 Sensitisation and Challenge of mice 
 
Sensitisation and challenge of mice was performed as described previously.11 
SM-MHCcreIL-4Rα-/lox, IL-4Rα-/lox and IL-4Rα-/- mice were sensitised with 50 µg 
Ovalbumin (Sigma-Aldrich, grade V) in 200µl PBS/ 1.3% Alum (Sigma-
Aldrich) on day 0, day 7 and day 14. On day 21, 22 and day 23, mice were 
anaesthetised with Ketamine (Centaur Labs, South Africa)/ Xylazine (Bayer, 
South Africa) and challenged with 1mg OVA in 50µl PBS by nasal 
administration. Control groups were treated identically except OVA was 
















3.3.6 Measurement of Airway Hyperreactivity 
 
Airway reactivity measurements were performed as described previously.11 
Anaesthetised and paralysed mice were mechanically ventilated and lung 
resistance was measured at baseline and following increasing intravenous 
doses of acetylcholine. 
 
3.3.7 Analysis of airway inflammation 
 
Lungs from sacrificed mice were flushed once with 1ml PBS/1% FCS to obtain 
bronchoalveolar lavage (BAL) fluid and total cell number was determined 
using a haemocytometer. For histological analysis, tissue samples were fixed 
in 4% phosphate-buffered formalin, cut in 5-7µm paraffin sections and stained 
with Periodic acid-Schiff reagent (PAS) or haematoxylin and eosin (H&E). 
Lung tissue was homogenized in Tris/ NP-40 buffer and then centrifuged for 
20 minutes at 20000rcf for mouse mast cell protease-1 (mMCP-1) ELISA and 
eosinophil Peroxidase (EPO) assay. A colorimetric assay for EPO was used 
to quantify eosinophils in the lung tissue.27 50 µl of the substrate solution 
consisting of 16mM o-phenylenediamine (Sigma-Aldrich) in 100mM Tris-HCl 
buffer pH 8.0 containing 0.1% Triton and 0.01% hydrogen peroxide was 
added to 50 µl tissue sample (protein concentration 1mg/ml) and peroxidase 
standard (Sigma-Aldrich) in 96 well plates. The reaction was stopped after 5 
minutes with 50µl 2M H2SO4 and absorption was measured at 490nm. Mouse 
mast cell protease concentrations were determined by ELISA (Moredum 
Scientific, UK) according to the manufacturer’s protocol. Serum eotaxin levels 

















3.3.8 Measurement of serum antibodies 
 
Blood samples were collected in plasma separator tubes (BD, USA) by tail 
vein bleeding and centrifuged for 15 minutes at 6000rcf. OVA-specific 
antibody isotypes were measured in blood serum by endpoint titration ELISA. 
Plates were coated with 5µg/ml (for IgG) or 1mg/ml (for IgE) OVA. AP-
conjugated anti-mouse isotype specific antibodies (Southern Biotechnology, 
USA) and 4-nitrophenyl phosphate (Fluka, CH) were used for detection. 
Absorbance was measured at 405nm with 492nm as a reference wavelength.  
 
3.3.9 Analysis of in vitro cytokine production 
 
For analysis of in vitro cytokine production splenocytes and lymphocytes were 
isolated from pooled spleens or mediastinal lymph nodes of OVA treated and 
control mice. Cells were incubated for 120h at 1x 106 cells/ml in 200µl IMDM 
(Gibco, UK)/10% FCS (Delta, South Africa) in 96well plates. Cells were 
stimulated with anti-CD3 antibodies (clone 145-2C11; 10µg/ml) and 
supernatants were collected after 120 hours. Concentrations of IL-4, IL-5, IL-
9, IFNγ (BD Biosciences, USA) and IL-13 (R&D Systems, USA) were 





Values are given as mean ± SD and significant differences determined using 



















3.4.1 Disruption of the il4ra gene in the airways of SM-MHCcreIL-
4Rα-/lox mice 
 
Smooth muscle cell specific disruption of the il4ra gene is achieved by cell 
specific expression of Cre recombinase. Here Cre expression excises the 
loxP flanked exons 7-9 from the il4ra gene in SM-MHCcreIL-4Rα-/lox mice 
(Fig.1A). Disruption of the il4ra gene was analysed at the genomic level by 
comparing the ratio of the exon 8 and exon 5 alleles in SM-MHCcreIL-4Rα-/lox 
and IL-4Rα-/lox control mice by quantitative real time-PCR. 
Exon 8 was significantly reduced in tracheal genomic DNA in SM-MHCcreIL-
4Rα-/lox mice when compared to IL-4Rα-/lox mice (p= 0.0407). In the spleen no 
differences were found in exon 8/exon 5 ratio between SM-MHCcreIL-4Rα-/lox 
and IL-4Rα-/lox mice (Fig.1B). To confirm specificity of gene disruption, α-actin 
enriched cell samples were obtained from lungs and trachea by cell sorting. 
The percentage of α-actin positive cells after purification was 69.94% for the 
SM-MHCcreIL-4Rα-/lox and 78.66% for the IL-4Rα-/lox mice. Analysis of smooth 
muscle cell enriched samples revealed a significant reduction of the ratio of 
exon 8 to exon 5 in SM-MHCcreIL-4Rα-/lox mice when compared to IL-4Rα-/lox 
mice (p= 0.0036). In purified CD4+ T cells the exon 8 to exon 5 ratio was 
equivalent in both mouse groups (Fig.1C).  
The effect of il4ra smooth muscle cell specific gene disruption was 
demonstrated by infection studies with the nematode Nippostrongylus 
brasiliensis. Such infections induce a Th2 dependent pulmonary pathology 
characterised by heightened airway mucus production.28, 29 In this study SM-
MHCcreIL-4Rα-/lox mice were found to have reduced mucus production at days 
7 and 10 post infection when compared to IL-4Rα-/lox mice. IL-4Rα-/- mice 














Taken together these results demonstrate a functional smooth muscle cell 
specific disruption of the il4ra gene in the airways of SM-MHCcreIL-4Rα-/lox 
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Figure 1. IL-4Rα deletion in smooth muscle cells of SM-MHCcre IL-4Rα-/lox mice. Black 
boxes represent exons of the il4ra gene locus in IL-4Rα-/lox, SM-MHCcre IL-4Rα-/lox and IL4Rα-/- 
mice (A). The ratio of IL-4Rα exon 8 to exon 5 alleles was determined by real-time PCR in 
genomic DNA samples from trachea and spleen tissue from IL-4Rα-/lox and SM-MHCcre IL-
4Rα-/lox mice (B). Smooth muscle cells from lung tissue were sorted after intracellular α-actin 
staining versus Isotype control. The ratio of IL-4Rα exon 8 to exon 5 alleles was determined 
by real-time PCR in genomic DNA samples from sorted smooth muscle cells and CD4+ T cells 
from IL-4Rα-/lox and SM-MHCcre IL-4Rα-/lox mice (C). Mucus producing goblet cells were 
stained with PAS in the airways of IL-4Rα-/lox, SM-MHCcre IL-4Rα-/lox and IL-4Rα-/- mice on day 














3.4.2 Allergen-induced airway hyperreactivity is not affected in 
SM-MHCcreIL-4Rα-/lox mice 
 
Airway reactivity was measured in sedated and paralyzed, mechanically 
ventilated SM-MHCcreIL-4Rα-/lox and IL-4Rα-/lox mice after OVA or saline 
challenge. Airway resistance was increased in allergen-challenged IL-4Rα-/lox 
and SM-MHCcreIL-4Rα-/lox mice, indicating the development of airway 
hyperreactivity. These increases in airway resistance were not observed in 
saline challenged mice. Similar increases in airway reactivity were seen inSM-
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Figure 2. Airway resistance is not affected by loss of the IL-4Rα on smooth muscle 
cells. Airway response to increase concentrations of Acetylcholine was measured in IL-4Rα-






















3.4.3 Airway infiltration with inflammatory cells and mucus 
production are not affected in SM-MHCcreIL-4Rα-/lox mice 
 
During allergic airway reactions, inflammatory cells infiltrate the lung tissue 
around blood vessels and airways. The alum treated control group failed to 
demonstrate any infiltration of the lungs by inflammatory cells (Fig. 3A). Both, 
IL-4Rα-/lox mice and SM-MHCcreIL-4Rα-/lox mice showed severe perivascular 
and peribronchial inflammation with eosinophil infiltration (Fig 3B,C), whereas 
IL-4Rα-/- mice showed mild signs of inflammation (Fig.3D). Hyperplasia of 
mucus-producing goblet cells in the lungs is a characteristic of allergic 
asthma. Histological examination of PAS stained lungs of OVA sensitized and 
challenged IL-4Rα-/lox mice and SM-MHCcreIL-4Rα-/lox mice showed similar 
severity of goblet cell hyperplasia (Fig. 3F,G), whereas the alum treated 
control group and IL-4Rα-/- mice showed no signs of increased mucus 
































Figure 3. Infiltration of the lung tissue with inflammatory cells and goblet cell 
hyperplasia after sensitisation and challenge with OVA is not affected by loss of the IL-
4Rα on smooth muscle cells. Lung sections from IL-4Rα-/lox mice sensitized and challenged 
with PBS (A) and OVA sensitised and challenged IL-4Rα-/lox (B), SM-MHCcreIL-4Rα-/lox (C) and 
IL-4Rα-/- mice (D) were stained with H&E. Mucus producing goblet cells were stained with 
PAS in the airways of PBS sensitized and challenged IL-4Rα-/lox mice (E) and OVA sensitized 
and challenged IL-4Rα-/lox (F), SM-MHCcre IL-4Rα-/lox (G) and IL-4Rα-/- mice (H). Pictures were 









Inflammatory cells are recruited to the lungs as a consequence of allergic 
sensitisation and challenge. The total number of cells in the BAL fluid of OVA 












recovered from IL-4Rα-/lox mice but was significantly higher than the cell 
number in the BAL fluid of IL-4Rα-/- mice (Fig 4A). To quantify the number of 
eosinophils in the lung tissue the amount of eosinophil peroxidase (EPO), 
which is stored in intracellular vesicles in eosinophils until activation, was 
measured in lung tissue lysate. There was no significant difference in the 
amount of EPO in the lung tissue between SM-MHCcreIL-4Rα-/lox mice and IL-
4Rα-/lox mice (Fig 4B). In IL-4Rα-/- mice, the concentration of EPO was 
significantly reduced compared to SM-MHCcreIL-4Rα-/lox mice but was higher 
than in PBS treated control mice. During allergic airway inflammation the lung 
tissue and airway smooth muscle cells are infiltrated by mast cells. The 
amount of mMCP-1, a marker for mast cell degranulation, was increased in 
the lung tissue after challenge with ovalbumin with no significant differences in 
all mouse strains (Fig. 4C).  
It has been shown that after in vitro stimulation with IL-13, airway smooth 
muscle cells release eotaxin, a chemoattractant for eosinophils. Levels of this 
chemokine were measured in the serum of OVA sensitised and challenged 
SM-MHCcreIL-4Rα-/lox, IL-4Rα-/lox and IL-4Rα-/- mice. Eotaxin concentrations 
were similar in both SM-MHCcreIL-4Rα-/lox and IL-4Rα-/lox mice but significantly 
lower in IL-4Rα-/- mice (Fig. 4D).  
These results show that SM-MHCcreIL-4Rα-/lox mice are not protected from 
allergic airway inflammation as is the case with IL-4Rα-/- mice, which showed 

















































































Figure 4. Markers of the lung inflammation are not affected by loss of the IL-4Rα on 
smooth muscle cells after sensitisation and challenge with OVA. Loss of the IL-4Rα on 
smooth muscle cells did not alter inflammatory response compared to control mice. Total cell 
number was counted in BAL fluid (A). Eosinophil peroxidase (B) and mMCP-1 (C) levels were 
measured in lung tissue lysate. Eotaxin concentration was measured in the blood serum by 
ELISA (D). Values represent pooled data with SD from two experiments with 4-6 mice per 
group. (**, p< 0.005) 
 
3.4.5 Th2 type cytokine and antibody responses are unaffected in 
SM-MHCcreIL-4Rα-/lox mice 
To determine whether T cell dependent immune responses were affected by 
disrupted smooth muscle cell IL-4Rα, splenocytes and lymphocytes from lung 
draining mediastinal lymph nodes were stimulated in vitro with anti CD3 
antibody after sensitization and challenge of SM-MHCcreIL-4Rα-/lox, IL-4Rα-/lox 
and IL-4Rα-/- mice with OVA. SM-MHCcreIL-4Rα-/lox and IL-4Rα-/lox mice 












IL-5, IL-9 and IL-13 compared to the IL-4Rα-/- mice. There was no significant 
difference in the cytokine levels between the SM-MHCcreIL-4Rα-/lox and IL-

































































































































Figure 5. Sensitisation and challenge with OVA induces a Th2 type immune response 
in IL-4Rα-/lox and SM-MHCcreIL-4Rα-/lox mice. Lymphocytes from mediastinal lymph nodes 
and splenocytes were restimulated in vitro with anti-CD3 antibody and cytokine 













To investigate whether antibody responses to allergens are affected by IL-
4Rα signalling on smooth muscle cells, specific antibody levels in SM-
MHCcreIL-4Rα-/lox mice were compared to those of IL-4Rα-/lox and IL-4Rα-/- 
mice after sensitisation and challenge with OVA. Compared to alum treated 
control groups, serum levels of OVA-specific IgG1 and IgE, were significantly 
increased in IL-4Rα-/lox and in SM-MHCcreIL-4Rα-/lox mice with no significant 
differences between the two mouse strains (Fig. 6A, B). As expected IL-4Rα-/- 
mice showed significantly increased levels of specific IgG2a and IgG2b (Fig. 
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Figure 6. The allergen specific antibody response of SM-MHCcreIL-4Rα-/lox mice 
resembles the antibody response of IL-4Rα-/lox mice. OVA specific antibodies were 
measured by endpoint titration ELISA. Tested subclasses were IgG1 (A), IgE (B), IgG2a (C) 
















To investigate the contribution of smooth muscle cell IL-4 and IL-13 signalling 
in the onset of allergic asthma in vivo, SM-MHCCreIL-4Rα-/lox mice were used, 
which have a cell specific disruption of IL-4Rα on smooth muscle cells. 
Comparison of these mice to IL-4Rα-/lox and IL-4Rα-/- mice showed that 
impaired IL-4Rα signalling in smooth muscle cells had no effect on the major 
aetiological markers of allergic asthma. 
 
The demonstration of il4ra gene disruption in ASMC of SM-MHCCreIL-4Rα-/lox  
mice in this study confirmed the integrity of this transgenic mouse. As 
expected the exon 8 to exon 5 ratio was significantly reduced in the trachea of 
SM-MHCCreIL-4Rα-/lox mice. Furthermore, enrichment of smooth muscle cells 
by cell sorting of α-actin positive cells from the lung further reduced the exon 
8 to exon 5 ratio. The proportion of α-actin negative cells in the purified 
smooth muscle cell population was 30%. This fact rather than inefficient 
disruption of IL-4Rα expression might explain why exon 8 copies were still 
detected in SM-MHCCreIL-4Rα-/lox mice. Cre-mediated cell specific gene 
disruption has been shown to be highly efficient in hemizygous IL-4Rα-/lox 
mice. In CD4+ T cell specific IL-4Rα Lckcre IL-4Ra -/lox mice, the efficiency of 
gene disruption was 95.48%.30 As a small number of ASMC might express 
functional IL-4Rα we tested SM-MHCCreIL-4Rα-/lox  mice in a disease model 
where IL-4Rα expression is a key mediator of the pathology.31 Following N. 
brasiliensis infection, mucus production in the airways of both IL-4Rα-/- mice 
and SM-MHCCreIL-4Rα-/lox mice was noticeably reduced. This phenotype is in 
agreement with previously published data where N. brasiliensis induced 
intestinal mucus production was also reduced in SM-MHCCreIL-4Rα-/lox mice. 14 
In conclusion, these data provided convincing evidence that SM-MHCCreIL-
4Rα-/lox mice have a smooth muscle cell specific disruption of the il4ra gene in 













Both SM-MHCCreIL-4Rα-/lox and IL-4Rα-/lox mice developed AHR after 
sensitisation and challenge with OVA, and equivalent responses to 
acetylcholine were seen in both groups. Furthermore, comparable levels of 
airway inflammation were observed in SM-MHCCreIL-4Rα-/lox and IL-4Rα-/lox 
mice following treatment with allergen. No difference in concentration of 
eotaxin in blood serum or eosinophilic inflammation of lung tissue was seen 
between SM-MHCCreIL-4Rα-/lox and IL-4Rα-/lox mice. As expected, IL-4Rα-/- 
mice failed to generate a hyperplasic goblet cell mucus response, however 
both SM-MHCCreIL-4Rα-/lox and IL-4Rα-/lox mice showed hyperplasic goblet cell 
driven mucus responses. Finally lymphocytes from SM-MHCCreIL-4Rα-/lox and 
IL-4Rα-/lox mice produced IL-4, IL-5, IL-9 and IL-13 in comparable amounts 
after in vitro stimulation and both mouse strains showed a Th2 type antibody 
response typical of allergic reactions.  
 
A recent study demonstrated that IL-4Rα signalling in epithelial cells is 
required for enhanced mucus production in response to allergens. Using mice 
with disrupted expression of IL-4Rα on clara cells (goblet cell precursors), it 
was possible to demonstrate a cell specific requirement for IL-4Rα for allergen 
induced mucus production in a non-immune cell type.11 Although epithelial cell 
IL-4Rα signalling was required for mucus production, it was not required for 
AHR.  
 
The finding that loss of IL-4Rα on smooth muscle cells had no effect on any of 
the major aetiological markers of allergic asthma is surprising. A large body of 
in vitro data indicated a contribution of smooth muscle cell IL-4Rα in allergic 
asthma. Several studies showed enhanced responses of cultured murine 
smooth muscle cells to contractile agonists after treatment with IL-4 and IL-13. 
12, 13, 32 In human smooth muscle cells, IL-13 increased intracellular Ca2+ 
responses induced by contractile agonists 12 and decreased responsiveness 
to bronchodilators.33 Based on these results it was believed that narrowing of 
the airways in allergic asthma was influenced by direct effects of IL-4 and IL-
13 on ASMC.  However, it was shown here that AHR in this model was 












to contractile agonists after treatment with IL-4 or IL-13 observed in vitro may 
be of little or no relevance to AHR development in vivo. Furthermore, it was 
shown that IL-4Rα signalling on smooth muscle cells is not essential for 
inflammatory responses and eotaxin release during acute phase allergic 
asthma. As lung endothelial cells express eotaxin in response to IL-13 34 in a 
STAT6 dependent manner 35 these cells may be responsible for the IL-4Rα 
dependent increases in serum eotaxin observed here contributing to the 
airway inflammation. On the other hand we have previously shown that direct 
effects of IL-13 on airway epithelial cells did not induce airway inflammation in 
vivo.36 
 
Using the SM-MHCCreIL-4Rα-/lox mice enabled us, for the first time, to test in 
vivo the assumptions about the role of IL-4Rα on ASMC derived from in vitro 
studies. No evidence was found to support an important role for smooth 
muscle cell IL-4Rα in allergic asthma. The presence of IL-4Rα on ASMC in 
allergic asthma was not, as previously suggested, critical for the disease 
outcome, highlighting the importance of in vivo studies of complex diseases 
such as allergic asthma which are characterised by complicated interactions 
of different cell populations. However, ASMC do have the ability to produce a 
wide range of cytokines and chemokines upon stimulation 37 which are likely 
to play an important immunoregulatory role in allergic asthma independent of 
direct responsiveness to IL-4Rα. Such candidates are likely to define the role 
of ASMCs in allergic asthma. 
 
The results presented here were derived from a mouse model of allergic 
asthma but the situation is likely to be similar in the human disease. As such 
the data presented here has important consequences for the development of 
new treatments of allergic asthma and therapies targeting IL-4Rα in the lung 
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4 Impaired Alternative Macrophages Activation does 






Development of alternatively activated macrophages (AAM) is induced by the 
Th2 cytokines IL-4 and IL-13 via the IL-4Rα. AAM have been associated with 
allergic asthma and parasite infections in clinical and experimental 
investigations but their role in the development of the disease is not defined. 
Therefore a model of acute allergic asthma was used to compare mice 
deficient in AAM with control mice. The contribution of AAM in experimental 
asthma was investigated using LysMcreIL-4Rα-/lox mice which have a 
macrophage/neutrophil specific disruption of the il4ra gene. These mice were 
compared to IL-4Rα deficient (IL-4Rα-/-) and normal control mice (IL-4Rα-/lox). 
 
Methods 
Allergic asthma was introduced in mice by repeated sensitisation with 
ovalbumin/ aluminium hydroxide on days 0, 7, 14, followed by intranasal 
allergen challenge on days 21-23. Mice were investigated for the presence of 
AAM in the lungs as well as airway hyperresponsiveness, airway 
inflammation, allergen specific antibody production, Th2 type cytokine 
responses and lung pathology. 
 
Results 
Whereas AAM, identified as Ym1 positive macrophages, were abundant in 
control mice after allergen challenge, only few were found in LysMcreIL-4Rα-/lox 
and IL-4Rα-/- mice. A typical Th2 cytokine response developed in LysMcreIL-
4Rα-/lox mice but production of IL-4 and IL-13 in CD4+ T cells was significantly 
impaired. Both LysMcreIL-4Rα-/lox and control IL-4Rα-/lox mice developed all the 
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hyperresponsiveness, airway inflammation and mucus production were not 
different in LysMcreIL-4Rα-/lox mice as from controls. 
 
Conclusion 
Despite the presence of AAM at early stages of allergic airway inflammation, 





Alternatively activated macrophages (AAM) are associated with human1, 2 and 
experimental allergic asthma, but their specific role in the pathology of this 
disease needs to be defined. In the study presented here their role in allergic 
airway disease was investigated using LysMcreIL-4Rα-/lox mice deficient in 
AAM.3  
Allergic asthma is a chronic disease of the airways characterised by 
inflammation of the airways, excessive mucus production in the airway 
epithelium, airway hyperresponsiveness and airway remodelling. A strong 
correlation between disease severity and the presence of T helper 2 (Th2) 
type cytokines, including IL-4, IL-5, IL-9 and IL-13, has been shown in clinical 
and experimental investigations. Models of experimental asthma highlight the 
importance of IL-4 and IL-13 and their shared receptor IL-4Rα for the 
development of main disease symptoms. Whereas IL-4 seems to be important 
for the initiation of the Th2 type immune response driving allergic asthma,4 
some of the main symptoms are dependent on IL-13.5 Mice deficient for IL-
4Rα show abrogation of airway hyperresponsiveness, hyperplasia of mucus-
producing goblet cells, allergen specific IgE and eosinophilic airway 
inflammation.6 This shows the general importance of the IL-4Rα for the 
development of allergic symptoms in experimental asthma, but the cell 
specific contributions of IL-4Rα signalling need to be identified.  
IL-4Rα responsive immune cells present in the allergic lung are involved in 
the development of asthmatic symptoms. Experimental allergic asthma is 
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sensitisation, is produced by B cells in an IL-4 dependent manner.7  Mast 
cells, basophils and eosinophils contribute to disease development by the 
release of inflammatory mediators like histamine or leukotrienes and may be 
important sources of IL-4 and IL-13.8, 9  
The most abundant immune cells in the healthy lung are macrophages 
residing in the alveolar spaces of the airways.10, 11 Along with epithelial cells 12 
macrophages control the innate immune defence in the airways and express a 
variety of pattern recognition receptors like mannose receptors or β-glucan 
receptors. Under disease conditions blood monocytes are recruited to the lung 
and differentiate into lung macrophages.13  In asthmatic patients 14-16 and in 
animal models of allergic asthma 17, 18 numbers of airway macrophages are 
increased. Such data suggest that macrophages play an important role in 
allergic inflammation of the lung, but their precise role needs to be defined. 
Experimental data is conflicting, demonstrating both suppression 19-22 and 
induction of allergic symptoms in mice.23 Despite the conflicting results, 
macrophages might play an important role in regulating inflammatory 
responses in the lung. 
Depending on the local cytokine environment, activated macrophages develop 
into different subsets. Th1 cytokines, especially IFN-γ, induce classical 
activation of macrophages which is characterised by secretion of 
proinflammatory cytokines and upregulation of inducible nitric oxide synthase 
(iNOS), resulting in nitric oxide (NO) production by hydrolysis of L-arginine. 
These so called classically activated macrophages (CAM) have antimicrobial, 
phagocytotic and proinflammatory functions. 
The Th2 cytokines IL-4 and IL-13 induce the development of alternatively 
activated macrophages (AAM) by signalling through IL-4Rα.13 Alternative 
activation induces arginase I expression whereas inducible nitric oxide 
synthase (iNOS) is suppressed.24 Synthesis of prolines, precursors of 
collagen, by arginase implicated an important role of AAM in tissue fibrosis 
and wound healing.13 AAM are distinct from classically activated 
macrophages (CAM) by the expression of the surface markers Ym1, 25, 26 
FIZZ1 27 and mMGL1/2 28  and upregulation of PPARγ 29 and mannose 
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recognition and phagocytosis but precise contributions of the specific markers 
in AAM function and disease development are not known. AAM have been 
shown to control obesity and insulin resistance in mice and might be beneficial 
for the prevention of diabetes.29 Elevated numbers of AAM are associated 
with several diseases including allergic asthma,2, 13 parasite infections 30, 31 
and lung fibrosis 32, 33 but a defined role in most diseases needs to be 
identified. Infection studies in mice with the nematode Heligmosomoides 
polygyrus showed that induction of AAM by memory Th2 cells mediated a 
protective immune response against the parasite.34 AAM were also essential 
for granuloma formation and the survival of mice after infection with 
Schistosoma mansoni by downregulating a harmful Th1 immune response.3 
Infection of mice with the nematode Nippostrongylus brasiliensis induces a 
strong Th2 type immune response and leads to the induction of AAM in the 
lung.35, 36 In mouse models of allergic asthma, AAM have been induced in the 
lung after allergen challenge. Development of chronic pulmonary 
Cryptococcus neoformans infection in mice was accompanied with induction 
of AAM leading to the development of symptoms similar to allergic asthma.37, 
38 Expression of the chitinases Ym1 and 2 in lung macrophages was 
dependent on IL-4Rα signalling in an OVA model of allergic asthma.26, 39, 40 In 
the same model, arginase I expression was upregulated in an IL-4Rα 
dependent manner 2 and its inhibition by RNA interference attenuated IL-13 
induced allergic symptoms.41 A recent study has shown that IL-13Rα1 
signalling is not necessary to induce AAM differentiation in a mouse model of 
allergic asthma suggesting that IL-4Rα signalling might be sufficient.42 In 
addition to the results from mouse models, AAM are also associated with 
human allergic asthma. Numbers of AAM in atopic patients were increased 
when compared to healthy control persons 1 and high numbers of arginase 
expressing macrophages could be found in the bronchalveolar lavage (BAL) 
from individuals with asthma.2 
These studies demonstrated an association of AAM with allergic asthma, 
suggesting an important role for these cells in the development of the disease. 
Nevertheless any contribution by AAM to the pathology remains to be defined. 
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AAM in the acute phase of ovalbumin induced allergic asthma in mice (Fig 
1A). LysMcreIL-4Rα-/lox mice have a cell specific disruption of the il4ra gene in 
macrophages and neutrophils (Fig. 1B) and are therefore unable to produce 
AAM.3 These mice allowed for the first time a direct investigation of the role of 
AAM in the development of allergic asthma.  
 




The generation and characterisation of IL-4Rα-/- and LysMcreIL-4Rα-/lox mice 
on a Balb/c genetic background was described previously.3, 43 Hemizygous IL-
4Rα-/lox mice were used as wild type control groups in all experiments (Fig. 
1A).3 The experiments were performed with 6-8 weeks old female animals. 
Mice were housed in the animal unit of the University of Cape Town under 
specific pathogen free barrier conditions using individually ventilated cages. 
All experiments were approved by the Research Animal Ethics Committee of 




The genotypes of mice were determined by PCR prior to the experiments as 
described previously 3. Specific PCR primer pairs were for the IL-4Rα 5’-
GTAC AGCGCACATTGTTTTT-3’ and 5’-CTCGGCGCACTGACCCATCT-3’; 
deletion 5’-GGCTGCCCTGGAATAACC-3’ and 5’-CCTTTGAGAACTGCGGG 
CT-3’; loxP 5’-CCCTTCCTGGCCCTGAATTT-3’ and 5’-GTTTCCTCCT 
ACCGCTGATT-3’; and Cre, 5’-ATGCCCAAGAAGAAGAGGAAGGT-3’ and 5’-
GAAATCAGTGCG TTCGA ACGCTAGA-3’. PCR conditions were as follows: 
94ºC for 1 min, 94ºC for 30 s, 57ºC for 30 s, and 72ºC for 1 min for 40 cycles 
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4.3.3 Allergen sensitisation and challenge 
 
The allergen sensitisation and challenge protocol to ovalbumin (OVA, grade 
V, Sigma, Germany) was described previously 18 and used with slight 
modifications. IL-4Rα-/lox, IL-4Rα-/- and LysMcreIL-4Rα-/lox mice were sensitised 
on day 0, 7 and 14 with 50µg OVA in 200µl PBS/ 1.3% aluminium hydroxide 
(Sigma) by intraperitoneal injection. On day 21, 22 and 23 mice were 
anaesthetised with 200µl Ketamine (Centaur Labs, South Africa)/ Xylazine 
(Bayer, South Africa) and challenged with 0.1mg OVA in 50µl PBS by 
intranasal administration. PBS control groups were treated identically except 
OVA was missing in the solutions. Airway hyperresponsiveness was 
measured on day 24 and mice were killed and analysed, on day 25 (Fig. 1B). 
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Figure 1. Experimental model of ovalbumin induced allergic airway disease in LysMcre 
IL-4Rα-/lox mice. Black boxes represent exons of the il4ra gene locus in IL-4Rα-/lox, LysMcre IL-
4Rα-/lox and IL4Rα-/- mice (A). Mice were sensitised intraperitoneally (i.p.) with 50µg 
ovalbumin (OVA) in 200µl PBS/ alum on day 0, 7 and 14. This was followed by 3 intranasal 
(i.n.) challenges of anesthetized mice with 0.1mg OVA in 50µl PBS. The PBS control group 
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4.3.4 Airway Hyperresponsiveness 
 
Responsiveness to β-methacholine (Sigma) was assessed in conscious 
unrestrained mice using a whole body plethysmograph (emka Technologies, 
France) and analysed with iox2 software (emka Technologies, France). This 
system measures pressure changes induced by the breathing of the mice and 
computes enhanced pause (Penh) values, a dimensionless parameter 
calculated by the formula 
 
Penh= (expiratory time / relaxation time-1)    
   x (peak expiratory flow / peak inspiratory flow) 44 
 
Increasing duration of the late phase of expiration relative to its early phase 
and increasing pressure change during expiration relative to the pressure 
change during inspiration results in increasing Penh values 45. It has been 
shown previously that changes in Penh values correlate with changes in 
airway resistance in the Balb/c mouse strain under similar conditions to those 
used in the present study.44, 46, 47 Individual mice were placed in 
plethysmograph chambers and baseline readings were measured for 5 
minutes before each exposure to increasing doses of aerosolised 
methacholine (0, 3.125, 6.25, 12.5, 25, 50 mg/ml methacholine in PBS). The 
response was measured for 15min after each nebulisation. Results are 
computed as the average of first 5 minutes minus the average of baseline 
reading. 
 
4.3.5 Serum antibodies 
 
Blood samples were taken by tail vein bleeding or directly from mice after 
killing and collected in plasma separator tubes (MicrotainerTM SST, BD, USA). 
Samples were centrifuged for 20min at 6000rcf and stored at -80ºC. OVA 
specific antibodies were measured in blood serum by endpoint titration ELISA. 
For antigen specific antibodies, 96 well ELISA plates (Maxisorp, Nunc, 
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IgG2a, IgG2b or 1mg/ml for IgE). For total IgE ELISA, plates were coated with 
anti-mouse IgE antibody (clone 84.1C, 1/1000 dilution). Plates were blocked 
for 1h at 37ºC with 200µl 2% fat free milk powder in PBS. Serial dilutions of 
serum samples in 50µl PBS/ 0.1% BSA were added to the wells and plates 
were incubated overnight at 4 ºC. Purified recombinant mouse IgE (BD, USA) 
was used as a standard for total IgE ELISA, at a starting concentration of 
1µg/ml. 50µl alkaline phosphatase conjugated goat anti-mouse isotype 
specific antibodies (Southern Biotechnology, USA) at a 1/1000 dilution in 
PBS/ 0.1% BSA were added to the wells and the plates were incubated for 3h 
at 37ºC. Subsequently, plates were incubated with 50µl p-
nitrophenylphosphate (Fluka, Switzerland) and colour reaction was stopped 
with 50µl 1M NaOH. Absorption was measured at 405nm with 492nm as 
reference wave length using a VersaMax plate reader (Molecular devices, 
USA). Plates were washed 4x with 200µl per well after each incubation step.  
 
4.3.6 Bronchoalveolar Lavage 
 
Mice were killed by CO2 asphyxiation and lungs were washed once with 1ml 
PBS through an 18G IV catheter (Braun, Germany). Recovered 
bronchoalveolar lavage (BAL) fluid (0.5-0.8ml) was centrifuged for 10min at 
400rcf and the cell pellet was resuspended in 0.5ml DMEM after lysis of red 
blood cells. Total cell numbers in the BAL fluid were determined in trypan blue 
(SIGMA, Germany) stained aliquots using a hematocytometer. A maximum of 
2x105 cells in 200µl was centrifuged on a microscope slide at 800rpm for 5min 
using a Cytospin centrifuge (Shandon, UK). The slides were air-dried and 
stained with Rapidiff Stain Set (Clinical Diagnostics CC, South Africa). 
Differential cell counts for eosinophils, neutrophils, lymphocytes and 
macrophages were made at 400x magnification and at least 100 cells were 
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4.3.7 Isolation of CD4+ cells 
 
CD4+ cells were purified from lung draining lymph nodes for in vitro 
restimulation experiments 48. Lymph nodes were removed from the mice and 
pooled in DMEM/ 2% FCS for each experimental group. Lymph nodes were 
pressed through a 70µm cell strainer (BD, USA) and cell suspensions were 
washed once with 10ml DMEM/ 2% FCS. Single cell suspensions were 
stained with anti-CD8 (clone 53.6.72), anti-CD11b (clone M1/70), anti-GR-1 
(clone RB68C5) and anti-B220 (clone RA36B2) antibodies at a concentration 
of 1x107 cells/ ml. Stained cells were depleted using goat anti-rat IgG Biomag 
magnetic beads (QIAGEN, Germany) at 1ml per 107 cells. 2x105 CD4+ cells 
per well were restimulated in anti-CD3 (clone 145-2C11, 10mg/ml) coated U-
bottom 96-well plates (Nunc, Denmark) for 96h in IMDM / 10% FCS at 37ºC. 
To determine the purity of the sorted cell populations, an aliquot was stained 
with anti-CD4-biotin (1:320 dilution, clone GK1.5) and Streptavidin-FITC 
(1:1000, BD, USA) dilution and analysed by FACS (FACS-Calibur, BD, USA). 
 
4.3.8 Cytokine ELISA 
 
Cytokine concentrations in the supernatant of in vitro restimulated CD4+ cells 
were determined by ELISA. Plates (Maxisorp, Nunc, Denmark) were coated 
overnight with 50µl anti-IL-4 (clone 11B11), anti-IL-5 (BD, USA), anti-IL13 
(R&D Systems, USA) or anti-IFNγ (clone AN18KL6) capture antibodies at 4ºC. 
Plates were blocked for 1h at 37ºC with 200µl 2% fat free milk powder in PBS. 
Samples or serial dilutions of recombinant cytokine standards (BD, USA) in 
50µl PBS/ 0.1% BSA were added to the wells and plates were incubated 
overnight at 4 ºC. Biotinylated secondary antibodies were added and the 
plates were incubated for 3h at 37ºC followed by horseradish peroxidase 
(HRP) labelled streptavidin for 1h at 37ºC. Subsequently plates were 
incubated with 50µl TMB Peroxidase Substrate (KPL, USA) and the colour 
reaction was stopped with 50µl 2M H2SO4. Absorption was measured at 










Chapter 4  
125 
(Molecular devices, USA). Plates were washed 4x with 200µl per well after 
each incubation step.  
 
4.3.9 Lung Histology and Immunohistochemistry 
 
Lung tissue was fixed in 4% Formaldehyde in PBS, embedded in paraffin and 
cut in 5-7µm sections. Sections were stained with Periodic acid-Schiff reagent 
(PAS) or haematoxylin and eosin (H&E). For immunohistochemistry, sections 
were rehydrated and blocked with 1% H2O2 in methanol. After antigen 
retrieval in 10mM citrate buffer pH6, sections were blocked with 0.1% Avidin 
followed by 0.01% biotin for 15 min. Sections were stained with biotinylated 
anti-mouse Ym1 antibody for 90 min (1/100 dilution, R&D Systems, USA) and 
HRP labelled streptavidin for 30 min (1/400 dilution). Stained section were 
developed with DAB substrate and counterstained with haematoxylin. 
 
4.3.10 Statistical Analysis 
 
Values are given as mean ± SD and significant differences were determined 






4.4.1 Ym1 expression in the lung after allergen challenge 
 
LysMcreIL-4Rα-/lox mice carry a disruption in the il4ra gene in macrophages, 
but not in other cell types. Ym1 is a member of the mammalian chitinase 
family and its expression is upregulated in alternatively activated 
macrophages and airway epithelial cells.27, 40 Tissue sections were stained 
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Compared to the PBS treated control group (Fig. 2A,E), OVA treatment 
resulted in highly increased numbers of Ym1 positive alveolar macrophages in 
control IL-4Rα-/lox mice (Fig. 2B,F). In LysMcreIL-4Rα-/lox mice (Fig. 2C,G) and 































Figure 2. Reduction of Ym1 expression in alveolar macrophages in LysMcre IL-4Rα-/lox 
and IL-4Rα-/- mice.  Lung sections of OVA treated and PBS control mice were stained with 
anti-Ym1 antibodies to identify Ym1 positive alveolar macrophages. (A-D) 400x magnification, 
(E-H) 1000x magnification. (I) Isotype control for Ym1 antibody. Mφ: macrophage. Data are 
representative of two experiments. 
 
 
Ym1 was also detected in lung epithelial cells and was upregulated in IL-4Rα-
/lox mice after OVA challenge (Fig. 3B), but not after PBS challenge (Fig. 3A). 
Ym1 expression in epithelial cells was reduced in LysMcreIL-4Rα-/lox mice (Fig. 
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mice (Fig. 3D). Negative staining of lung sections from OVA treated IL-4Rα-/lox 






















Figure 3. Impaired Ym1 expression in airway epithelium of LysMcreIL-4Rα-/lox and IL-
4Rα-/- mice. Lung sections of OVA treated and PBS control mice were stained with anti-Ym1 
antibodies to identify positive airway epithelial cells (A-D). Isotype control for Ym1 antibody 
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4.4.2 Cytokine response of CD4+ T cells from lung draining lymph 
nodes 
 
Development of allergic asthma is driven by Th2 cytokines and Th2 type T 
cells are considered an important source of IL-4, IL-5 and IL-13. To determine 
whether T cell dependent immune responses were affected by disrupted IL-
4Rα on macrophages, sorted CD4+ T cells from lung draining lymph nodes 
were stimulated in vitro with anti-CD3 antibody after sensitization and after 
challenge of LysMcreIL-4Rα-/lox, IL-4Rα-/lox and IL-4Rα-/- mice with OVA. Purity 
of the sorted CD4+ cell populations was 94-98% as determined by FACS 
analysis (Fig. 4A). LysMcreIL-4Rα-/lox and IL-4Rα-/lox mice showed a polarised 
Th2 type cytokine response with elevated concentrations of IL-4, IL-5 and IL-
13 when compared to PBS treated IL-4Rα-/lox mice and low IFN-γ production. 
The Th2 type cytokine response from CD4+ cells of LysMcreIL-4Rα-/lox mice, in 
particular the production of IL-4 and IL-13, was significantly reduced when 
compared to IL-4Rα-/lox mice. IL-4Rα-/- mice showed a Th1 polarized cytokine 


























































































Figure 4. Impaired cytokine production in CD4+ cells from lung draining lymph nodes of 
LysMcreIL-4Rα-/lox mice. (A) Purity of sorted CD4+ cells was confirmed by anti-CD4 FITC 
staining and FACS analysis. (B) Cytokine secretion of CD4+ cells from lung draining lymph 
nodes cultured with anti-CD3 antibodies was measured by IL-4, IL-5, IL-13 and IFN-γ specific 
ELISA. Data are representative of two experiments ± SD. (**p<0.01; **p<0.01; ***p<0.001 
significant differences from OVA sensitised and challenged IL-4Rα-/lox mice) 
 
 
4.4.3 Airway hyperresponsiveness and airway inflammation 
 
Hyperresponsiveness of the airways to nonspecific bronchoconstrictors is 
characteristic of allergic asthma. After OVA sensitisation and challenge, mice 
were exposed to increasing doses of aerosolized β-methacholine and airway 
hyperresponsiveness was determined by whole body plethysmography. No 
significant differences were detected between OVA treated LysMcreIL-4Rα-/lox 
and IL-4Rα-/lox mice. Both groups developed a dose dependent AHR, reflected 
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above the PBS treated control group after challenge with 25 and 50mg β-
methacholine. As previously shown7, AHR in OVA treated IL-4Rα-/- mice was 
abrogated and comparable to the PBS treated IL-4Rα-/lox mice (Fig. 5A).  
In allergic asthma, bronchi and alveoli are infiltrated by inflammatory cells with 
eosinophils being the characteristic cell type. Total numbers of inflammatory 
cells in the BAL fluid were not significantly different between OVA treated IL-
4Rα-/lox (6.4x105), LysMcreIL-4Rα-/lox (5.9x105) and IL-4Rα-/- (4.3x105) mice, but 
were increased compared to PBS treated IL-4Rα-/lox mice (Fig. 5B). Equal 
numbers of eosinophils were found in IL-4Rα-/lox and LysMCreIL-4Rα-/lox mice 
whereas in IL-4Rα-/- mice eosinophils were significantly reduced (Fig. 5C). No 
significant differences in numbers of neutrophils, lymphocytes and 
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Figure 5. Allergic airway response of LysMcreIL-4Rα-/lox mice is similar to response in IL-
4Rα-/lox mice. Airway responsiveness to Methacholine was measured by whole body 
plethysmography and represented as Penh values (A). Total (B) and  differential (C) cell 
numbers were determined in BAL fluid. Pooled data of two experiments ± SD. (*p<0.05; 
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4.4.4 Lung histology 
 
During allergic airway reactions, inflammatory cells infiltrate the lung tissue 
around blood vessels and airways. IL-4Rα-/lox (Fig. 6B), LysMcreIL-4Rα-/lox (Fig. 
6C) and IL-4Rα-/- mice (Fig. 6D) showed perivascular and peribronchial 
inflammation while the alum treated control group failed to demonstrate any 
infiltration of the lungs by inflammatory cells (Fig.6A). H&E staining of lung 
sections showed that eosinophils were present in the inflammatory cell 
infiltrate in both LysMcreIL-4Rα-/lox (Fig. 6G) and IL-4Rα-/lox mice (Fig. 6F), 
whereas this cell type was absent in IL-4Rα-/- mice (Fig. 6H). Hyperplasia of 
mucus producing goblet cells in the lungs is a characteristic of allergic 
asthma. Histological examination of PAS stained lungs of OVA sensitized and 
challenged LysMcreIL-4Rα-/lox and IL-4Rα-/lox mice showed similar severity of 
goblet cell hyperplasia (Fig. 6B,C) whereas the alum treated control group and 



















































Figure 6. Similar lung pathology in LysMcreIL-4Rα-/lox mice and IL-4Rα-/lox mice after 
allergen challenge. (A-D) Lung sections of OVA treated and PBS control mice were stained 
with PAS. G: mucus producting goblet cells; I: inflammatory infiltrate. 100x magnification. (E-
H) Lung sections of OVA treated and PBS control mice were stained with H&E. E: 





4.4.5 Antibody response 
 
To investigate whether antibody responses after sensitization and challenge 
with allergens are affected by IL-4Rα signaling on macrophages, specific 
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/lox and IL-4Rα-/- mice after sensitisation and challenge with OVA. Compared 
to alum treated control groups, serum levels of OVA specific IgE (Fig. 7A) and 
IgG1 (Fig. 7C) were increased in IL-4Rα-/lox and in LysMcreIL-4Rα-/lox mice with 
no significant differences between the two mouse strains. As expected, IL-
4Rα-/- mice showed highly increased levels of specific IgG2a and IgG2b (Fig. 
7D,E) but impaired OVA specific IgE and IgG1 (Fig. 7A,C) antibody titres.7 In 
accordance with the specific antibody response, total IgE concentrations were 
elevated after allergen sensitisation and challenge in IL-4Rα-/lox and LysMcreIL-
4Rα-/lox mice but not in IL-4Rα-/- or PBS treated IL-4Rα-/lox mice (Fig. 7B).  
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Figure 7. Allergen specific antibody response of LysMcreIL-4Rα-/lox mice resembles 
antibody response of IL-4Rα-/lox mice. Serum concentrations of antibodies were determined 
by ELISA. Pooled data of two experiments ± SD. (*** p<0.001; ** p<0.01 significant 





















Alternatively activated macrophages have been associated with allergic 
asthma in a number of studies, but no particular function in the development 
of the disease has been defined so far.2, 26, 39-41 The LysMcreIL-4Rα-/lox mouse 
model, which is unable to launch AAM responses, allows the in vivo 
investigation of the role of alternatively activated macrophages in different 
disease models. Use of these mice has demonstrated important roles for AAM 
in several studies. For example, it has been shown that survival of 
Schistosoma mansoni infections and the prevention of obesity is dependent 
on the presence of AAM.3, 29 Other studies have shown important roles for 
AAM in memory responses to nematode infections34 and an association with 
allergic diseases.26, 39, 40 Together these results indicated important roles for 
AAM in Th2 driven pathologies, including allergic asthma. Therefore, 
LysMcreIL-4Rα-/lox mice were used in a model of acute allergic lung 
inflammation induced by ovalbumin to investigate the cell specific 
contributions of alternatively activated macrophages to the acute phase of 
allergic airway inflammation.  
This study showed that development of allergic asthma in LysMcreIL-4Rα-/lox 
mice was associated with impaired induction of AAM and significantly reduced 
cytokine responses in the lung. Despite these effects key pathological 
markers of ovalbumin induced allergic airway disease remained unaffected. 
Impaired AAM development in LysMcreIL-4Rα-/lox mice was confirmed by 
strongly reduced numbers of Ym1 positive macrophages after allergen 
challenge when compared to IL-4Rα-/lox control mice. Macrophage Ym1 
expression was not completely abrogated in LysMcreIL-4Rα-/lox, IL-4Rα-/- and 
PBS control mice, in agreement with previous observations of additional IL-
4Rα and Th2-independent control of Ym1 expression in macrophages 36. Ym1 
was also detected in airway epithelial cells of IL-4Rα-/lox mice but not IL-4Rα-/- 
mice. Reduced Ym1 expression in airway epithelial cells of LysMcreIL-4Rα-/lox 
mice compared to IL-4Rα-/lox mice implicates an important role for IL-4Rα 
expression in macrophages. Alternative activation of macrophages might 
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in the airway epithelium. IL-13 dependent Ym1 expression in the airway 
epithelium has been described 40 and the results presented here suggest a 
new regulatory role for AAM. There is a possibility that IL-4Rα expression in 
LysMcreIL-4Rα-/lox mice is not only disrupted in macrophages but also in 
epithelial cells, but this explanation is unlikely as epithelial cell specific 
disruption of the il4ra gene leads to impaired mucus production 17 which was 
not observed here.  
A Th2 type immune response was observed in the lung draining lymph nodes 
of IL-4Rα-/lox and LysMcreIL-4Rα-/lox mice after allergen challenge. However, in 
LysMcreIL-4Rα-/lox mice production of the Th2 cytokines IL-4, IL-5 and IL-13 in 
lung draining lymph nodes was impaired but not directed towards a Th1 type 
response as IFN-γ production was not elevated as it was in IL-4Rα-/- mice. 
The reduced Th2 type cytokine response in LysMcreIL-4Rα-/lox mice did not 
result in the reduction of allergic symptoms and were sufficient for induction of 
a type 2 antibody response with high levels of IgE and IgG1. Mouse 30, 31 and 
human 49 AAM are able to inhibit T cell proliferation and activation and 
downmodulate cytokine responses. By contrast the results presented here 
show higher cytokine production in the presence of AAM. This might be due to 
the reduction of Ym1 production in the lung of LysMcreIL-4Rα-/lox mice. Ym1 
and other chitinases like AMCase are not only associated with and 
upregulated during allergic airway responses but have also been shown to 
positively influence the development of a Th2 immune response.50  
Despite the strong reduction of AAM numbers in the lung after allergen 
challenge and an impaired Th2 cytokine response in lung draining lymph 
nodes, the pathology of allergic asthma was not altered in LysMcreIL-4Rα-/lox 
mice when compared to IL-4Rα-/lox mice. Allergen specific antibody production 
was virtually identical in LysMcreIL-4Rα-/lox and IL-4Rα-/lox mice. This suggests 
that AAM are not critical in the sensitisation phase of allergic responses when 
a Th2 type memory response against the allergen is established.  
Airway hyperresponsiveness was not affected in LysMcreIL-4Rα-/lox mice, 
demonstrating that IL-4Rα signals in macrophages and neutrophils are not 
involved here. Interestingly the cellular composition of inflammatory cells in 
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mice. Numbers of neutrophils, macrophages and eosinophils did not differ 
between LysMcreIL-4Rα-/lox mice and IL-4Rα-/lox mice. Furthermore, 
eosinophils were present after allergen challenge in the peribronchial 
inflammatory infiltrate of IL-4Rα-/lox and LysMcreIL-4Rα-/lox mice. These results 
show that AAM are not required for the development of eosinophilic 
inflammation in allergic asthma. Involvement of AAM in eosinophil recruitment 
has been suggested in mouse models of nematode infections.51, 52 These 
different observations might due to differences between mouse models of 
nematode infection and allergic asthma. Furthermore, involvement of 
eosinophil recruitment was only correlated to Ym1 expression in macrophages 
51 or demonstrated indirectly in op/op mice 52 which show impaired 
macrophage development. By using LysMcreIL-4Rα-/lox mice the present study 
showed directly that AAM are not necessary for eosinophil recruitment in 
allergic asthma.   
In summary, the contribution of AAM to the onset of allergic asthma was 
investigated using LysMcreIL-4Rα-/lox mice with a macrophage/ neutrophil 
specific disruption of the il4ra gene. AAM were present in the early stages of 
allergic airway inflammation in IL-4Rα-/lox mice but not in LysMcreIL-4Rα-/lox 
mice. Previous studies have shown that AAM are induced during allergic 
asthma and the work presented here is in agreement with these observations. 
However, based on the results presented here this recruitment does not play 
a role in acute allergic airway pathology. A role for AAM in the chronic phase 
of allergic asthma has been proposed and future work will aim to define 
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5 Conclusions and future work 
5.1 Anisakis related allergies 
 
The aim of this study was to compare the impact of two clinically important 
sensitisation routes to Anisakis pegreffii, namely infection with live Anisakis 
worms and sensitisation to Anisakis extract by inhalation1, 2 on the outcome of 
experimental allergic asthma. We found allergic airway disease to be 
equivalent in both experimental scenarios and wild type Balb/c mice 
developed airway hyperresponsiveness (AHR), goblet cell hyperplasia and 
airway eosinophilia after allergen challenge.  
Two findings in this study were of special interest as they were dependent on 
the sensitisation route. 
In wild type mice, sensitisation via the nasal route induced AHR, goblet cell 
hyperplasia and airway eosinophilia independent of allergen specific antibody 
responses. However, Anisakis specific IgE could not be detected and total IgE 
levels were not affected by sensitisation. Antigen specific IgG1 was found at 
low levels compared to Anisakis live infection where mice developed a robust 
allergen specific IgE and IgG1 response.  
Development of allergic symptoms in the absence of IgE has been described 
in mouse and human studies. Whereas IgE was not necessary for the 
development of allergic symptoms, Th2 cytokines were required in mice3-5 and 
elevated in human patients.6-8 In agreement with these data, sensitisation via 
the nasal route induced allergen specific Th2 type cytokine responses and 
development of allergic symptoms in the absence of allergen specific 
antibodies.  
Anisakis infected mice developed IL-4Rα-independent airway 
hyperresponsiveness in the absence of other typical allergic symptoms such 
as specific IgE, goblet cell hyperplasia and Th2 type immune responses. 
Interestingly, IL-4Rα independent AHR was dependent on the route of 
sensitisation as development of AHR after nasal sensitisation was impaired in 













symptoms,9, 10 but development of IL-4Rα independent AHR has been 
reported.11 However, IL-4Rα independent AHR required IL-13 and IL-5 11 and 
production of both cytokines was impaired in the lymph nodes of IL-4Rα 
deficient mice in our study. Other sources of IL-13 might be responsible for 
the development of IL-4Rα independent AHR after Anisakis live infection. A 
mechanism that does not involve IL-13 is another explanation for the 
development of AHR in IL-4Rα deficient mice. High numbers of neutrophils in 
the BAL were found after allergen challenge and neutrophilic asthma has 
been described in human patients. The relation of neutrophils with clinical 
asthma pathology in is not understood and a mechanism for disease 
development is not known.12  
 
In both sensitisation protocols, AHR could be induced in the absence of 
allergen specific IgE. This suggests that non-atopic individuals could also 
develop Anisakis induced airway symptoms. Diagnosis of Anisakis allergies 
often relies on the detection of specific IgE 13, 14 and our results may be 
important especially for the in the occupational environment where nasal 
sensitisation plays an important role in disease development 1, 15, 16. Absence 
of specific IgE might not be sufficient to rule out Anisakis allergy, especially in 
cases of occupational asthma. 
Furthermore, we found several potential Anisakis pegreffii allergens. A 35 kDa 
allergen, identified by Western blot analysis, has been identified previously in 
our laboratory in human and animal studies (unpublished data). No Anisakis 
allergen of this size is found in the literature or allergen data bases 
(http://www.allergen.org) but Anisakis allergens are described for the species 
A.simplex. This 35 kDa protein might represent a specific allergen for the 
species A.pegreffii. The identification of a specific allergen may be important 
for the diagnosis of Anisakis allergy in South Africa as this species is 
commonly found local fish and a significant cause of allergy. 
Indeed, in South Africa fish consumption is common what increases risk of 
developing Anisakis related diseases 2 and a high prevalence of Anisakis 













particular Ascaris lumbricoides, are a common problem in South Africa 17 and 
could be linked to an increased risk of developing allergy to cross-reactive 
allergens.18, 19 As cross-reactivity between Anisakis and Ascaris allergens has 
been shown 20 it would be important to investigate whether Ascaris infection is 
able to predispose an individual to Anisakis induced allergies. In order to 
develop reliable diagnostic tools, allergens of Anisakis pegreffii need to be 
characterised and are currently under investigation in our department. Further 
studies are necessary in order to obtain a better picture of the local situation 
and to develop prevention strategies and public awareness for the problem. It 
is also important to understand the immunological mechanisms that are 
responsible for the development of allergic reactions in order to provide 
effective therapies and diagnostic tools for allergic patients. 
 
5.2 IL-4Rα in the development of allergic asthma 
 
The general importance of IL-4Rα in the development of allergic diseases and 
in particular allergic asthma has been shown in mouse models of the disease 
and in human studies.21-23 However, specific roles for IL-4Rα in the disease 
especially its role on different cell types is only partially understood. 
Transgenic mice with cell type specific disruptions of the il4ra gene are an 
excellent tool for addressing this question. Such cell specific models are 
relatively new, yet have already yielded substantial data of the cell specific 
contribution of IL-4Rα in experimental allergy models. For example IL-4Rα 
dependent murine anaphylaxis has been shown to be driven by IL-4Rα 
expression on CD4+ T cells, but not macrophages.24 A study using transgenic 
mice with an epithelial cell specific il4ra gene disruption has demonstrated 
that goblet cell hyperplasia and mucus production to be critically dependent 
on IL-4Rα expression in these cells in experimental asthma.25  
The present study expands on this knowledge by demonstrating the role of IL-
4Rα expression on macrophages and smooth muscle cells in experimental 













demonstrated that ovalbumin and Anisakis protein extract have similar effects 
on the onset of allergic airway disease when compared in the experimental 
protocol used in the study presented here. Therefore, results obtained here 
are also relevant for Anisakis induced allergic disease. 
Previous studies have demonstrated a critical role of IL-4Rα expression on 
macrophages 26 and smooth muscle cells 27 in different models of parasite 
infections. However, in both mouse models we found no significant 
contribution of IL-4Rα in the onset of experimental allergic airway disease. 
Airway hyperresponsiveness (AHR) and airway inflammation are key features 
of allergic asthma and in vitro data have strongly suggested a direct 
contribution of IL-4Rα signalling on ASMC to these pathologies.28 In vitro 
stimulation of ASMC with IL-4/IL-13 increased the contractile response 29, 30 
and resulted in release of cytokines such as eotaxin,31, 32 TARC 33 and 
VEGF.34 However, the present study showed that AHR and airway 
inflammation was independent of IL-4Rα signals on ASMC. This is a 
surprising and significant result which suggests other signals to be 
responsible for ASMC contraction and recruitment of inflammatory cells in 
allergic asthma and future research needs to focus on the identification of 
these signals.   
In addition to ASMC, AAM are also associated with the onset of experimental 
and human allergic asthma.35 In the study presented here, AAM were 
abundant in the early stages of allergic airway disease, but no specific role in 
the acute phase of allergic airway disease could be defined. Important 
contributions to disease development were expected as AAM express several 
molecules associated with allergic asthma such as arginase and Ym1. AAM 
upregulate arginase expression upon activation35 and inhibition of arginase 
attenuated IL-13 induced AHR.36 Expression of chitinases such as AMCase 37 
and Ym1 38 is regulated by IL-13 in macrophages and airway epithelial cells 39 
in experimental and human asthma and a regulatory role for Th2 type immune 
responses has been proposed for these molecules. In the study presented 
here we found impaired Ym1 expression in macrophages and airway 













production in lung draining lymph nodes. However, the development of a Th2 
type immune response and asthmatic symptoms was not affected and LysMcre 
IL-4Rα-/lox mice displayed all key features of the disease, although the Th2 
type cytokine response was impaired in lung draining lymph nodes. AAM have 
been associated with recruitment of eosinophils in murine helminth 
infections.40 However, in our model of experimental asthma, the development 
of airway eosinophilia was not dependent on AAM. LysMcreIL-4Rα-/lox mice are 
only deficient in IL-4Rα activated AAM and other types of macrophages with 
similar properties as are found, such as IL-10 activated macrophages.35 
Furthermore, the Cre/loxp system does not provide disruption in 100% of the 
target cells.41 Ym1, a marker for AAM, was still expressed in macrophages of 
LysMcreIL-4Rα-/lox mice and these cells might compensate for the loss of IL-
4Rα activated macrophages. 
This study highlighted the usefulness of cell type specific IL-4Rα deficient 
mice and in vivo disease models for gaining a better understanding of the 
mechanisms behind allergic airway diseases. Previous studies suggested 
important IL-4Rα dependent contributions for ASMC 28 as well as AAM 35 to 
the development of allergic airway disease but these conclusions were 
derived from in vitro experiment with ASMC or from associations of AAM with 
the disease. Cell type specific IL-4Rα deficient mice allow a direct and 
convenient investigation of the role of this receptor in the development of 
allergic diseases and the results presented here demonstrated this clearly. 
However, IL-4Rα signal on ASMC and AAM may play an important role in the 
development of chronic allergic asthma. The present study used mouse 
models of the acute early phase of the disease and chronic effects were not 
addressed. Involvement of ASMC and AAM in airway remodelling, an effect of 
chronic allergic airway disease, has been suggested and IL-4Rα signalling 
may contribute to tissue fibrosis 35 and proliferation of smooth muscle cells 
around the airways.28 Future work will concentrate on mouse models of 














Furthermore, the mechanism behind IL-4Rα dependent disease development 
in the early and chronic phase of allergic airway inflammation will be 
investigated in additional cell type specific transgenic mice. In particular, cell 
specific contributions of the IL-4Rα in T cells, B cells and dendritic cells are of 
interest as these cells are believed to be crucial for induction of Th2 type 
cytokine responses, allergen specific IgE and IgG production and allergen 
presentation to T cells.  
The present study showed the importance of the route of sensitisation and IL-
4Rα in development of allergic diseases. In the past years substantial 
progress has been made in the understanding of immunological mechanisms 
behind allergies, but many aspects remain obscure. Research in this exciting 
field will continue in future and is necessary to provide new therapeutic 
strategies.   
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